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Alzheimer’s disease (AD) is a complex and multifactorial disease with the possible involvement 
of several genes.  Complex diseases such as AD have a large affect on the public health.  It was 
estimated in 2007 that over 5 million Americans had AD, and more than $91 billion dollars was 
spent by medicare on AD and other dementias.  Genetics plays a significant role in the etiology 
of the disease, therefore, it is of public health importance that the genetics of AD be investigated.  
With the exception of the APOE gene as a susceptibility marker no other genes have been 
identified for late-onset AD (LOAD).  A recent genome wide association study of 17,343 gene-
based putative functional single nucleotide polymorphisms (SNPs) found 19 significant variants, 
including 3 linked to APOE, showing association with  LOAD in several population samples.  
We have set out to replicate the 16 new significant associations in a large case-control cohort of 
American Whites.  Additionally we examined six variants present in positional and/or biological 
candidate genes for AD.  We genotyped the 22 SNPs in up to 1,009 Caucasian Americans with 
LOAD and up to 1,010 age matched older healthy Caucasian Americans.  All variants were 
genotyped using 5’ nuclease assays.  We did not observe a statistically significant association 
between the SNPs with the risk of AD, either individually or stratified by APOE.  Our data 
suggest that the association of the studied variants with LOAD, if it exists, is not statistically 
significant in our population study. 
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1.0  BACKGROUND 
1.1 INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder most commonly found in individuals 
over the age of 65.  AD can be classified by the age at onset (AAO), and family history.  Familial 
AD is classified by a significant family history of AD, and sporadic AD is classified by a lack of 
significant family history.  These categories can be further delineated by early-onset (<60 years 
of age) and late-onset (≥60 years of age). Sporadic AD is the most common form, making up 
approximately 90% of cases, familial AD makes up the remaining ~10%.  Three genes have been 
implicated in the etiology of early onset AD with an autosomal dominant mode of inheritance: 
amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2).  These genes 
have been found to make up approximately 50% of early onset AD, and they explain <1% of all 
AD cases (Kamboh, 2004).  Even with the investigation of these three genes the exact etiology of 
early onset AD is unknown.  Late onset Alzheimer’s disease (LOAD) has been particularly 
difficult to research due to its complexity, it is thought to be a multifactorial condition in which 
genes and environment play a role.  The only known genetic risk factor for LOAD is 
apolipoprotein E (APOE) (Kamboh, 2004).   
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1.2 EPIDEMIOLOGY OF ALZHEIMER’S DISEASE 
In 2007 it was estimated that 5.1 million Americans had AD, 4.9 million of these individuals are 
age 65 or older (Alzheimer’s association, 2007).  Advances in medicine have lead to more 
individuals living into their 80s and 90s.  The risk of AD increases with age, therefore the 
number of persons with the disease is expected to grow as individuals continue to live longer.  In 
2005, Medicare spent $91 billion on AD and other dementias, projected to increase to $160 and 
$189 billion in 2010 and 2015 (Alzheimer’s Association, 2007).  State and federally funded 
Medicaid spent $21 billion in 2005 on AD and other dementias.  This is projected to increase to 
$24 and $27 billion in 2010 and 2015 respectively (Alzheimer’s Association, 2007).  One study 
looked at the cost of institutional care in AD.  The median nursing home length of stay was 2.75 
years (mean 2.95, 95% CI = 2.5, 3.4), over 10 times the national median length of stay for all 
diagnoses (Welch et al. 1992). Nursing home charges for the cohort were estimated to be 
$35,000-$52,000 per patient.  A prolonged period of institutionalization combined with the high 
expense of nursing home care makes the costs of AD extensive. 
1.3 DIAGNOSIS AND PATHOGENESIS 
In order to study AD it is vital to determine the AAO.  It is difficult to determine the exact age of 
diagnosis.  Less severe symptoms may be present for a considerable amount of time before a 
diagnosis is made.  Diagnosis can be classified as possible or probable with a clinical diagnosis.  
Probable AD is when the individual has no other illness that may contribute to the symptoms.  
Possible AD is when the individual meets the criteria for another illness that may contribute to 
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his or her cognitive decline.   Clinical diagnosis is made by assessing clinical characteristics such 
as; progressive decline in memory and intellectual ability, declining language and speech skills 
and loss of orientation.  Most but not all diagnoses can be made clinically, a definitive diagnosis 
can only be made after death by a brain biopsy.  There are two pathological features of AD; 
extra-cellular senile plaques and the presence of intracellular neurofibrillary tangles.   
Extra-cellular senile plaques mainly consist of a 42 amino-acid amyloid β peptide (Aβ) 
derived from amyloid precursor protein (APP).  APP is a transmembrane protein that can be 
cleaved by β or α and γ secretase.  If APP is cleaved by α and γ secretase a harmless soluble 
protein is produced.  If APP is cleaved by β and γ secretase a peptide of 39-43 amino acids is 
produced.  The Aβ peptide-42 which is approximately 10% of the total product is considered 
harmful, and may lead to the generation of damaging plaques (Maccioni et al., 2001).  These 
plaques can occur outside and between neurons, affecting brain function or in the cerebral blood 
vessels, causing vascular damage such as senile cerebral amyloid angiopathy.  Cerebral amyloid 
angiopathy is a type of disease of the blood vessels, in which Aβ peptide-42 deposits in the walls 
of the blood vessels of the brain.  This build up makes these blood vessels more likely to fail, 
which increases the risk of stroke.  The deposition of Aβ peptide also interferes with calcium 
regulation and neurotransmission, generates free radicals which cause mitochondrial damage and 
causes inflammation, all of which lead to cell death. (Chen et al., 2007).  
Intracellular neurofibrillary tangles occur within neurons and involve the protein, Tau.  
The normal function of Tau is to associate with microtubules, which function to support the cell 
and transport nutrients through the cytoplasm.  Microtubules are made of the protein tubulin, Tau 
associates with tubulin and provides stability to microtubules in the cytoplasm.  Tau’s common 
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state is hypophosphorylation, however in AD Tau is hyperphosphorylated.  This 
hyperphosphorylation causes self aggregation of Tau, and inhibits Tau’s ability to associate with 
tubulin and microtubules.  This leads to the death of neurons due to lack of cellular stability and 
inability to transport nutrients. (Maccioni et al., 2001). 
1.4 ENVIRONMENTAL RISK FACTORS FOR LOAD 
LOAD is considered a multifactorial condition in which interaction of genes and environmental 
factors are involved in the etiology of the condition.  While investigating genetic factors in a 
multifactorial condition it is important to take into account environmental factors that may be 
confounding results.  Some possible environmental risk factors for LOAD include education, 
tobacco usage, alcoholism, head trauma, cerebrovascular disease, higher cholesterol level, etc.  
Gender also seems to affect the risk of AD with the disease being more common in females than 
males.  Although there is a multitude of possible risk factors, most of the data is questionable.  
The only proven risk factor for AD is age.   
1.4.1 Education:   
It has been proposed that a low level of education is a risk factor for sporadic LOAD.  In contrast 
a higher level of education may be associated with later onset of the disease.  One study indicates 
that up to a 4-5 year delay in the onset of AD is possible with a higher level of education 
(Katzman et al., 1993).  One theory is that those who are more educated are better equipped to 
compensate for neurological damage.  Therefore, they can sustain damage for longer without 
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showing symptoms of the disease.  There are confounding factors that make it difficult to 
specifically look at education and onset of AD.  Those who are less educated may have jobs that 
involve manual labor, these types of occupations may make them more likely to be exposed to 
toxic substances, and head trauma (Letenneur et al., 1999).  However, other studies have refuted 
this hypothesis that lower education level makes one more susceptible to Alzheimer’s disease.  
Moritz and Petitti (1993) reported results in which those with a lower education level had a later 
onset of disease.  However, once the clinical symptoms manifested they were severe.  This data 
may have been confounded by the fact that those with lower education were diagnosed at a later 
time due to failure to detect symptoms.  A recent study contradicts the hypothesis that level of 
education is positively correlated with an earlier onset of disease.  Mejia et al. (2003) reported 
that 8% of individuals examined with high level education (7-14 years) were found to have had 
an early onset of their disease.  However, other factors that influence education level may be 
confounding the data.  Studies may classify AAO by the first appearance of symptoms reported 
by the patient’s family.  A lower or higher education level may confound the time at which 
symptoms are detected.  For example, it may be more difficult to detect cognitive delay in 
patients that have less education.  Symptoms may not be noticed as soon in those with lower 
education and less cognitive and occupational demands.  Family members of those with a higher 
education level may notice neurologic deficits sooner, due to the fact that they may have greater 
occupational and non-occupational demands (Mejia et al., 2003).  Studies have noted that the 
years of education may not be affecting the onset of AD.  Rather, when an individual passes a 
threshold of education their risk may decrease (Letenneur et al., 1999).  Any study looking at 
education and its risk on AD is confounded by participant rate according to education. 
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1.4.2 Gender:   
One study found a higher incidence of AD in women than men after 80, however the incidence 
was higher in men before the age of 80 (Letenneur et al., 1999).  This study looked at other 
dementias and did not see this same trend.  Incidence of these conditions decreased in both sexes 
after the age of 85.  When the subjects were corrected for educational level the difference 
between the onset and sex remained.  Another study reported a higher incidence of dementia or 
AD in women, however, the population only consisted of subjects over 85 and 75 years of age 
(Gussekloo et al., 1995).  Other studies have found no association in the incidence of AD and the 
sex of the individual (Bachman et al., 1993).  Some possible explanations as to why women 
seem to be at a higher risk for AD are biological such as: genetics and hormonal differences.   
 
1.4.3 Tobacco and Alcohol Usage:   
Epidemiological studies have found conflicting tobacco affects on the risk of AD.  There are 
many confounding factors that come into play when studying AD and tobacco use.  Many studies 
that found smoking to have a protective effect on AD, did not control for sex, occupational 
categories and educational level (Letenneur et al., 2004).  When these confounding factors are 
taken into account tobacco use has been found to be a slight risk factor or have no affect on the 
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risk of AD.  A study conducted on 3,770 subjects looked at current smokers, past smokers and 
never smokers.  A small association was seen, the percentage of subjects with probable or 
possible AD was almost the same in current and past smokers with never smokers have he lowest 
incidence of AD.  However, when confounding factors were taken into account such as 
education level and occupation the association disappeared (Letenneur et al., 2004).  Alcohol 
consumption in relation to AD has been examined in several studies.  A prospective study in 
Sweeden on 402 subjects found a reduction of risk when individuals were light to moderate 
drinkers compared to non drinkers (alcohol included beer, wine and hard alcohol)(Letenneur et 
al., 2004).  When APOE genotyping was taken into account the reduction was more evident in 
those that carry the APOE*4 risk allele.  Compared to non-drinkers the risk of developing AD 
was decreased 1.8-fold for light drinkers and by 4-fold for mild drinkers (Letenneur et al., 2004).  
Observation does not prove that alcohol is a causal link to AD.  Selection bias may skew the 
results of the studies.  It is possible that only the healthier drinkers were captured by the study.  
This confounding factor could explain the slight protective association observed.  Other factors 
such as lifestyle and diet were also not controlled for. 
 
1.4.4 Head Trauma:   
A study done in 2000 by Guo et al. (2000) examined head injury and its affect on individual’s 
risk for AD.  Their results indicate that severity of head injury is related to the magnitude of AD 
risk.  Head injury with loss of consciousness was seen to have a greater effect than head injury 
without loss of consciousness.  Contrary to other studies the results from Guo et al. (2000) 
indicate that head injury had a greater affect on risk among those without the APOE*4 allele 
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compared with those having one or two APOE*4 alleles.  This study also looked at the affect of 
head trauma and sex.  They did not find a significantly higher association of head trauma and 
risk of AD between women and men.  Although this study found an increased risk for AD, with 
severe head trauma, they did not observe a difference in the AAO between patients with and 
without head injury.  There is a possibility that these results may be the confounded by recall 
bias.  Another study examined association between recurrent concussions and AD in professional 
football players (Guskiewicz et al., 2005).  This study indicated an association between AAO 
and head injury, but did not find an association between previous concussions and lifetime onset 
of AD.  This study found that concussions sustained by players may promote an earlier 
expression of AD, however, the factor of age eventually overwhelms this factor and prevents it 
from becoming an independent predictor of lifetime onset of AD (Guskiewicz et al., 2005).  This 
study also stated that cognitive status of the athletes with repeated trauma is influenced by age, 
APOE status, and cumulative exposure to head trauma.  Another study looked at chronic 
traumatic brain injury in boxing and risk of AD.  This study found that boxers with low exposure 
to brain injury had low brain injury scores irrespective of APOE.  However, in the group with 
high exposure to brain injury, those with APOE*4 showed a higher amount of brain injury than 
those without APOE*4.  The APOE*4 allele was associated with an increased severity of 
neurological deficits in the high exposure boxers in this study (Jordan et al., 1997). 
 
1.4.5 Vascular Disease 
Studies have suggested an association between vascular factors pre-disposing to cerebrovascular 
disease and AD.  Cerebrovascular disease is any disease in which the arteries in the brain or 
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arteries connected to the brain are blocked or defective.  Stroke and other events that lead to a 
restriction of blood supply have been seen to increase an individual’s risk of AD by up to three 
times (Kalaria et al., 2003).  This is most likely due to the increased stress on the brain caused by 
these events.  Some predisposing factors to cerebrovascular disease include: hypertension, atrial 
fibrillation, carotid thickening, aortic sclerosis and diabetes. 
 
1.4.6 Cholesterol Levels 
Lipids may play an important role in APP processing which leads to production of the 42 amino-
acid Amyloid β peptide (Aβ).  The action of γ secretase takes place in the lipid membrane.  
Therefore, the lipid environment of the membrane may play a role in enzyme activity and the 
development of Aβ and AD (Hartmann et al., 2007).  The brain is the most cholesterol rich organ 
in the body, synthesis, removal, storage or transport within the brain is strictly regulated 
(Hartmann et al., 2007).  Hypercholesterolemia was found to be an early risk factor for the 
development of Aβ in a longitudinal, population-based study (Kivipelto et al., 2001).  Although 
the exact role of cholesterol in AD pathogenesis is unknown, there is evidence that there is a 
dose dependent relationship between the level of cholesterol and the average onset of AD.  A 
study in which cholesterol synthesis was inhibited in animals or extracted, the amount of Aβ was 
seen to decrease in cerebrospinal fluid and the brain (Fassbender et al., 2001).  An increase in 
cholesterol levels is a risk factor to cerebrovascular disease which is also a possible risk factor 
for the onset of AD. 
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1.5 GENETIC SUSCEPTIBILITY 
1.5.1 Genetics of Early Onset Alzheimer’s Disease 
Alzheimer’s disease is most commonly seen in individuals age 65 or older.  However, AD still 
accounts for 30% of all nontraumatic dementia in individuals 30-64 years of age (Filley et al., 
2007).  In early onset AD patients an autosomal dominant inheritance has been observed with 
mutations in PSEN1, PSEN2 or APP.  PSEN1 mutations are the most commonly observed, and 
make up approximately 50% of familial early onset AD cases.  However, they only account for 
about 1% of all AD cases (Filley et al., 2007).  APP mutations have been observed in 
approximately 5-7% of familial early onset AD, and PSEN2 accounts for less than 1% (Filley et 
al., 2007). 
PSEN1 is located at chromosome 14q24.3, PSEN2 at 1q41, and APP at 21q21.2.  There 
have been a number of mutations reported in these genes; over 164 in PSEN1, ~28 in APP and 
~10 in PSEN2, as of October, 2007 (Alzheimer Disease & Frontotemporal Dementia Mutation 
Database).    
PSEN1 and PSEN2 are both located in the tissues of the brain.  They are comparable in 
size and are both located in similar intracellular compartments such as the endoplasmic reticulum 
and cytoplasm.  Different studies have investigated the function of these proteins.  PSEN1 has 
been hypothesized to play a roll in cell adhesion, and PSEN1 and PSEN2 have been visualized in 
association with interphase kinetochores and centromeres, which may suggest that the proteins 
play a role in chromosome organization and segregation (Filey et al., 2007).  It has been 
suggested that mutations in PSEN1 and PSEN2 may interfere with normal APP processing and 
lead to the AD.  PSEN 1 has been reported to be necessary for the activation of γ secretase.  It 
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remains to be determined whether PSEN1 is a transmembrane aspartyl protease, γ secretase co-
factor, or assists in the colocalization of γ secretase and APP.  It has been hypothesized that gain 
of function mutations in PSEN1 lead to an increased γ secretase activity, and therefore a higher 
rate of formation of senile plaques (online mendelian inheritance of man). 
 
1.5.2 Genetics of Late Onset Alzheimer’s Disease 
Late onset AD does not show a clear inheritence pattern, and therefore indicates multifactorial 
inheritance.  Most cases of LOAD are sporadic.  However, first degree relatives of an individual 
with AD are at a higher risk than the general population.  Survey and data from Cupples et al. 
(2004) found that substantial portions of relatives of those with AD, are interested in more fully 
understanding their risk.  Liddell et al. (2001) reported a predicted risk of developing AD in the 
first degree relatives of probands with AD of 15-19% compared with 5% in the general 
population, or a 3 to 4 fold increased risk.    
The only susceptibility maker found to be associated with LOAD has been  
apolipoprotein E (APOE), located on chromosome 19q13.  APOE consists of three common 
alleles: APOE*2, APOE*3 and APOE*4, with variation at codon 112 and 158.  The APOE*3 
allele is the most common in the general population.  The APOE*4 allele has been found to 
significantly increase one’s risk to AD, while the APOE*2 allele seems to be protective. 
APOE*4 is common in the U.S. population with a frequency of about 14% (Cupples et al., 
2004).  The APOE*4 allele has a dose related relationship with LOAD, two copies lead to an 
earlier age of onset (mean age before 70), and one copy leads to a latter age of onset (means age 
after 70) (Nussbaum et al., 2004).  The odds of AD are increased 3 times among those that carry 
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one copy of the APOE*4 allele, and 15 times among those that carry two copies of the APOE*4 
allele (Merikangas et al., 2003). 
APOE plays a vital role in the transport of cholesterol and other lipids through the body, 
and has been linked to the central nervous system.  It is hypothesized to be involved with the 
mobilization and redistribution of cholesterol, and in the repair, growth and maintenance of 
myelin and neuronal membranes during development and injury (Panza, 2004).  Studies have 
found that in AD patients, APOE*4 tends to co-localize with Aβ plaques in the brain.  In vitro 
studies have also found APOE*4 to have a stimulatory role in the formation of Aβ plaques.  
Although the exact pathology of the relationship between APOE*4 and LOAD is unknown, it 
has been suggested that APOE*4 may bind with greater affinity to Aβ plaques and serve as a 
chaperone in their formation (Panza, 2004).  APOE*3 and APOE*2 may bind with less affinity, 
this could explain why these individuals do not show in increase in disease.  The degree to which 
APOE status affects one’s risk is also dependent on age.  The older an individual is the less the 
affect of APOE*4 on AD, with little to no affect by the age of 90 (Kamboh, 2004). 
 
1.5.3 Genome Wide Association Studies 
Since sequencing of the human genome has been completed, SNP-based genome wide 
association studies have become possible.  These studies examine the whole genome for SNP 
association to specific diseases, instead of examining SNPs that are biological and/or positional 
candidates.  Alleles in genes across the whole genome can now be studied for significant 
association to multifactorial conditions (Coon et al., 2007). 
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In a genome wide association study examining 17,343 putative functional SNPs located 
in 11221 unique genes, 19 SNPs were found to have a statistically significant association with 
AD (Grupe, et al., 2007).  Of these 3 SNPs were present in the APOE ancestry genes and thus 
reflect the known association of APOE with AD.  Our goal was to replicate the other new 16 
associations in a large case-control sample of white Americans.  Additionally we examined six 
positional and/or biological candidates as risk factors for AD (SNP 17-22).  Five of these SNPs 
were identified in a paper investigating association with risk of coronary artery disease (Samani, 
et al., 2007).  It is possible that these SNPs are also biological candidates for risk of AD.  This is 
exemplified by APOE, which is a known risk factor for both coronary artery disease and AD. 
SNP17 is located between 10q11.1 and 10q11.2, in close proximity to choline 
acyltransferase (CHAT) a biological candidate gene that has been implicated in association with 
AD, due to its role in cholinergic neurotransmission (Kamboh, 2004).  Cholinergic 
neurotransmission is part of the nervous system that releases or is activated by acetylcholine or a 
related compound.  One of the earliest pathologic events in AD is thought to be the degeneration 
of cholinergic neurons of the basal forebrain (Auld et al., 2002).  Research showing a decrease in 
choline acetyltransferase (ChAT) activity (30-90%), ChAT mRNA (~50%) in the temporal lobe 
and frontal and parietal corticies of the AD brain, has further implicated CHAT in AD risk (Auld 
et al., 2002).  This gene has been previously investigated for a possible association with LOAD.  
Harold et al. (2003) indicated that polymorphisms in CHAT were probably not the primary cause 
of LOAD.  The authors of this study also commented that their results do not rule out CHAT as a 
possible risk factor for AD, but further investigation is needed.  SNP18 is located between 2q36 
and 2q37, with the closest gene located at 2q36.3.  SNP19 is located in the SMAD family 
member 3 gene (SMAD3), at 15q22.33.  Scott et al. (2003) found a linkage peak for AD on 
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chromosome 15q22 with a peak LOD score of 2.8 in 38 families with minimum age at onset >79 
years, and a peak LOD score of 3.1 in 43 families with mean age at onset >80 years.  SMAD3 is 
known to be associated with transforming growth factor beta 1 (TGF-β1). TGF-β1 is known to 
be associated with factors that may affect phosphorylation of tau (Ueberham et al., 2006).  
Ueberham et al. (2006) suggests that SMAD proteins may play a critical role in the pathogenesis 
of AD.  SNP20 is located between 9p21 and 9p22, with the closest gene located at 9p21.3.  
Several studies have identified linkage peaks for AD at 9p22 (Kehoe et al., 1999; Meyers et al., 
2004; Pericak-Vance et al., 2000; Haines et al., 2001), and at 9p21 (Blacker et al., 2003).  SNP21 
is located in the methylenetetrahydrofolate dehydrogenase gene (MTHFD1L) at 6q25.1.  A 
genome wide scan for AD in 466 families, Pericak-Vance et al. (2000) reported a linkage peak at 
the telomeric end of chromosome 6 spanning the region of 6q25.1.  MTHFD1L is involved in the 
enzymatic reaction transforming homocysteine to methyionine, and when not functioning 
correctly has been linked as a possible risk factor of AD.  Homocysteine is thought to exhibit 
pro-oxidative activity, and oxidative stress is one factor implicated as a risk for AD (Dorszewska 
et al., 2007).  Studies have also shown that homocysteine can pass the blood/brain barrier to have 
a larger affect on the CNS (Agnati et al., 2005).  Ho et al. (2002) hypothesized that elevated 
homocysteine levels may cause vascular damage, deteriorate function of the blood/brain barrier 
and cause abnormal nitrogen oxide production, all of which may increase the risk of AD.   SNP 
22 is located in the transcription factor7-like 2 gene (TCF7L2) at 10q25.3.  Several studies have 
found linkage peaks for AD spanning the 10q25.3 region (Kehoe et al., 1999; Li et al., 2002; 
Blacker et al., 2003).  TCF7L2 has been studied as a possible biological risk factor of Diabetes 
(Grant et al., 2006).  Research has also been done in order to determine if there is a link between 
diabetes and AD.  Although an exact link has not been identified, the possible link of TCF7L2 
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with diabetes, and the possible link of diabetes and AD makes TCF7L2 a possible biologic 
candidate for AD risk (Sima et al., 2006).  
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2.0  PATIENTS AND METHODS 
2.1 SUBJECTS 
2.1.1 Sample Population 
Subjects were 2,029 Caucasian American individuals.  The cases included 1,009 Caucasian 
Americans diagnosed with LOAD.  In this group 67.69% were female and 7.8% were autopsy 
confirmed.  The mean AAO was 72.85 ± (SD) 6.24 years.  The controls included 1,010 age-
matched healthy Caucasian Americans.  In this group 59.80% were female and 1,29% were 
autopsy confirmed.  The mean age at baseline was 74.07 ± 6.20 years.  The subjects were 
recruited with informed consent and the study was approved by the University of Pittsburgh 
Institute Review Board.   
DNA was isolated from blood using the QIAamp blood DNA Maxi kit protocol (Qiagen, 
Valencia CA), and from brain tissue using the QIAamp DNA Mini kit protocol.  A small number 
of samples with a low amount of DNA were amplified using the GenomiPhi kit (GE Healthcare). 
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2.2 GENOTYPE DETERMINATION 
2.2.1 TaqMan Assay 
The genotypes were determined using TaqMan SNP Genotyping Assays (Applied Bio Sysytems, 
Foster City, CA).  The assay identification numbers for each SNP are listed in Table 2.1.  
Table 2.1 TaqMan SNP genotyping assays 
SNP Gene location allele reference number TaqMan 
Genotyping Assay 
1 GALP 19q13.42 C / G rs3745833 C___1936853_1_ 
2 PCK1 20q13.31 A / G rs8192708 C___2508722_10 
3 TNK1 17p13.1 A / T rs1554948 C___8717889_1_ 
4 SERPINA13 14q31-14q32 A / T rs11622883 C___2188996_10 
5 PGBD1 6p22.1 A / G rs3800324 C__25942411_20 
6 LMNA 1q21.2-1q21.3 A / G rs505058 C____6303747_10 
7 UBD 6p21.3 C / G rs444013 C____588691_20 
8 UBA52P1 
Closest gene 7p15.2  
7p15 C / T rs1859849 C__11827509_10 
9 BCR 22q11.2-22q12 C / T rs9608099 C___2447571_1_ 
10 MYH13 17p13 C / T rs2074877 C___2179030_1_ 
11 EBF3 10q26.3 C / T rs11016976 C__10057645_10 
12 AGC1 15q26.1 G / T rs2882676 C___1834284_10 
13 CTSS 1q21 A / G  C__15746640_10 
14 FAM63A 1q21.2 A / T  C__22274641_10 
15 TRAK2 2q33 C / T rs13022344 C___1226613_10 
16 LOC442265 
Closest gene 6q24.1 
6q24 A / G rs6907175  
17 near CHAT 10q11.1-10q11.2 A / G rs501120 C___1033658_10 
18 LOC646736 
Closest gene 2q36.3 
2q36-2q37 A / C rs2943634 C__15949769_10 
19 SMAD3 15q22.33 C / T rs17228212 C__33991364_10 
20 LOC729983 
Closest gene 9p21.3 
9p22-9p21 C / G rs1333049 C__1754666_10 
21 MTHRD1L 6q25.1 A / G rs6922269 C__29894051_10 
22 TCF7L2 10q25.3 C / T rs7901695 C____384583_10 
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The TaqMan analysis was performed after all samples were placed on 384 well plates.  
Every plate had a mixture of cases and controls, and ten percent of the samples were repeated in 
order to assess error rate.  Formula and cycling conditions were followed according to Applied 
BioSystems TaqMan protocol. 
The biochemical principle of TaqMan is outlined briefly as follows.  TaqMan involves 
first the amplification of the DNA followed by reading using the7900HT Fast Real-Time PCR 
system machine (Applied Biosystems).  The samples are placed on a 384 well plate.  A mixture 
is then added to the samples which contains master mix, genotyping assay and water.  The 
genotyping assay consists of sequence specific forward and reverse primers, one probe labeled at 
the 5’ end with VIC dye and one probe labeled at the 5’ end with FAM dye.  A nonfluorescent 
quencher is attached to the 3’ end of each of these probes.  The probes lie between the two 
primers and overlay the SNP of interest. 
AmpliTaq Gold® Polymerase with 5’ exo-nuclease activity is used in the PCR reaction.  
During the annealing process the polymerase binds to the primers and begins elongation of the 
new DNA strand.  The polymerase removes DNA downstream impeding its ability to synthesize 
a new strand.  Therefore, when the polymerase reaches the attached probe during elongation the 
5’ exo-nuclease activity cleaves the probe.  This is only true for probes that bind with the target 
sequence.  Those probes that do not bind with the target sequence remain in tact in the solution, 
these probes are not able to fluoresce due to the fact that the VIC/FAM dye remains close to the 
quencher.  The probes that are cleaved, allow for the VIC/FAM dye to separate from the 
quencher.  This allows for the dye to fluoresce.  This reaction is illustrated in Figure 1.      
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Figure 1TaqMan Chemical Reaction 
The product is analyzed using the 7900HT Fast Real-Time PCR system.  The 
fluorescence of each product is measured, and placed on a graph accordingly.  The output allows 
us to distinguish between the different clusters of fluorescence intensity that are seen for each 
genotype.  An example of the results from a TaqMan analysis can be viewed in Figure 2. 
 
Figure 2 Results From TaqMan Analysis 
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2.3 STATISTICAL METHODS 
Allele and genotype frequencies were calculated by the direct allele-counting method.  Goodness 
of fit to Hardy-Weinberg equilibrium was tested using the X² test.  Differences between 
genotype and allele frequencies in case and controls were tested with the X² or Fisher’s exact 
tests as appropriate.  These statistics were calculated using R 2.2.0 with the genetics package 
attached (R Development Core Team, 2005).  
Genotype and allele frequencies for cases and controls were stratified for: APOE status, 
age at onset (AAO), diagnosis method (autopsy vs clinical), and classification of probable vs 
possible AD.  Analysis of variance for AAO, disease duration (age at death – age at diagnosis), 
and Mini-Mental state examination (MMSE) at baseline and change in score was calculated.   
We tested the hypothesis of Grupe et al. (2007) that the 16 identified SNPs were risk loci 
for AD.  We used the risk alleles identified in the paper and coded our population in order to 
determine how many risk alleles they carried total (assuming a dosage model) and how many 
loci contained a risk allele (assuming a dominance model).  We carried out a linear regression for 
each model adjusting for age, sex and APOE status.  These calculations, as well as linear 
regression for odds ratios, were done using R 2.2.0 with the genetics package attached.  Power 
estimation was made by calculating for a population size of 1,000 cases and 1,000 controls.   
In our analysis we chose not to examine interactions between the SNPs.  This was due to 
the fact that no specific association was seen with any of the SNPs individually.  Since we were 
examining so many SNPs a large amount of tests would have to be run.  It is quite possible that 
interactions may be found by chance due the number of SNPs.  Using the Bonferroni correction 
every time we do another test the p value gets smaller and smaller, making it more difficult to 
find a significant association.    
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3.0  RESULTS 
3.1 APOE POLYMORPHISM IN AD CASES AND CONTROLS 
APOE genotype frequencies are presented in Table 3.1. In cases the 3/4 genotype was the most 
frequent making up 46% of the total case genotypes. The 3/3 genotype was the second most 
frequent making up 38% of the total case genotypes.  The rest of the genotypes in the cases were 
below 10%. In controls the 3/3 genotype was the most frequent making up 65% of the total 
control genotypes.  The rest of the genotypes in the controls were below 20%.   While the 
frequency of the APOE*4 allele was significantly higher in cases than controls (p<0.001) the 
frequency of the APOE*2 allele was lower in cases than controls (p<0.001).  
 
Table 3.1. APOE polymorphism AD cases and controls 
APOE 
 AD Cases  Controls 
 n % n % 
3/3 386 0.38 656 0.65 
3/4 467 0.46 168 0.17 
2/3 39 0.04 143 0.14 
2/4 27 0.03 23 0.02 
4/4 87 0.09 14 0.01 
2/2 2 0.002 5 0.005 
Total (n) 1,008 1,009 
APOE*3 (1278) 0.63 (1623) 0.80 p< 0.001 
APOE*4 (668) 0.33 (219) 0.11 p<0.001 
APOE*2 (70) 0.004 (176) 0.009 p<0.001 
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3.2 GENOTYPE RATE 
The genotyping error rate for all the SNPs but SNP 18 was estimated to be <1%, the estimated 
error rate for SNP 18 was 2.8%.  The genotyping failure rate for all SNPs besides SNP16 was 
<1.14%, the failure rate for SNP16 was 4%. 
3.3 HARDY WEINBERG EQUILIBRIUM FOR 22 SNPS 
P-values based on Hardy Weinberg (HWE) equilibrium analysis are listed in Table 3.2.  Twenty-
one SNPs were in HWE, however, SNP2  PCK1 was found to be out of HWE with a p value of 
2.569 E-36 for cases and 1.401 E-29 for controls.  A search through NCBI found three groups 
reporting genotype and allele frequencies for this SNP.  These groups include HapMap 
(ss44233834), Perlegen (ss24451444) and University of Washington headed by Debra Nickerson 
(ss66859094) (dbSNP).  The allele frequencies with these studies, as well as Grupe et al. (2007) 
were similar to ours, but the genotype frequencies were not.  The data from NCBI and the Grupe 
et al. (2007) were in HWE.  When we examined the plots read from TaqMan, the clusters were 
distinct, and the calls were conservative.  Each plate individually was also not within HWE, the 
magnitudes of the p values were similar for each of the plates.  The cases and controls showed 
the same effect with similar p values.  The pattern in all of the plates in cases and controls, was 
an excess of both homozygotes and a shortage of heterozygotes in our data.   
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Table 3.2. P-values based on HWE for cases and controls 
 p value cases p value controls 
SNP1  GALP  rs3745833 0.501 0.645 
SNP2  PCK1  rs8192708           2.569E-36 1.401E-29 
SNP3  TNK1  rs1554948 0.570 0.131 
SNP4  SERPINA13  rs11622883 0.871 0.713 
SNP5  PGBD1  rs3800324 0.168 0.308 
SNP6  LAMIN AC  rs505058 0.054 0.790 
SNP7  UBD   rs444013 0.189 0.117 
SNP8  rs1859849 0.433 0.200 
SNP9  BCR  rs9608099 0.175 0.911 
SNP10  MYH13  rs2074877 0.429 0.132 
SNP11  EBF3  rs11016976 0.672 0.187 
SNP12  AGC1  rs2882676 0.330 0.842 
SNP13  CTSS 0.429 0.063 
SNP14  FAM63A 0.325 0.057 
SNP15  TRAK2  rs13022344 0.550 0.910 
SNP16  rs6907175 0.002 0.914 
SNP17 rs501120 0.449 0.660 
SNP18 rs2943634 0.173 0.253 
SNP19  SMAD3 rs17228212 0.259 0.108 
SNP20 rs1333049 0.435 0.090 
SNP21  MTHRD1L rs6922269 0.831 0.957 
SNP22  TCF7L2 rs7901695 0.778 0.327 
 
3.4 DISTRIBUTION OF 22 SNPS IN CASES AND CONTROLS  
Allele and genotype frequencies for 22 SNPs for cases and controls are given in Table 3.3.  No 
significant difference was found except for SNP 2 PCK1 rs3745833 which showed a marginal 
difference between genotype frequencies (p=0.057) and allele frequencies (p=0.015).   
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Table 3.3. Distribution of 22 SNPs in cases and controls 
      Genotype  n(%)              Allele  
     n          CC                       CG                    GG    p   C             G    p 
SNP1 
GALP   
rs3745833        
AD 1008 426 (0.423) 466 (0.462) 116 (0.115) 0.424 0.654 0.346 0.198 
C 1005 401 (0.399) 473 (0.471) 131 (0.130) 0.634 0.366 
     n         AA                       AG                    GG    p   A             G    p 
SNP2 
PCK1   
rs8192708        
AD 1009 807 (0.800) 139 (0.138) 63 (0.115) 0.057 0.869 0.131 0.015 
C 1008 762 (0.756) 173 (0.172) 73 (0.130) 0.842 0.158 
     n         AA                       AT                      TT    p   A             T    p 
SNP3 
TNK1 
rs1554948        
AD 1009 187 (0.185) 505 (0.500) 317 (0.314) 0.101 0.436 0.564 0.115 
C 1006 225 (0.224) 476 (0.473) 305 (0.303) 0.460 0.540 
     n         AA                       AT                      TT p A             T    p 
SNP4 
SERPINA13 
rs11622883      
AD 1007 216 (0.214) 498 (0.495) 293 (0.291) 0.931 0.462 0.538 0.955 
C 1004 212 (0.211) 505 (0.503) 287 (0.286) 0.463 0.537 
     n         AA                      AG                      GG    p   A             G    p 
SNP5 
PGBD1   
rs3800324        
AD 1009 0 (0.000) 84 (0.083) 925 (0.917) 0.411 0.042 0.958 0.974 
C 1002 3 (0.003) 77 (0.077) 922 (0.920) 0.041 0.959 
     n         CC                       CT                       TT    p   A             T    p 
SNP6 
LAMIN AC 
rs505058          
AD 1009 16 (0.185) 173 (0.500) 820 (0.314) 0.101 0.436 0.564 0.115 
C 1006 10 (0.224) 173 (0.473) 822 (0.303) 0.460 0.540 
     n         CC                       CG                      GG    p   C             G    p 
SNP7 
UBD  
rs444013       
AD 1009 255 (0.253) 525 (0.520) 229 (0.227) 0.049 0.513 0.487 0.168 
C 996 297 (0.298) 471 (0.473) 228 (0.229) 0.535 0.465 
     n         CC                       CG                      GG    p   C             G    p 
SNP 8 
rs1859849        
AD 1009 59 (0.058) 389 (0.386) 561 (0.556) 0.276 0.251 0.749 0.491 
C 1003 76 (0.076) 371 (0.370) 556 (0.554) 0.261 0.739 
     n         TT                        TC                       CC    p   T             C    p 
SNP9 
BCR 
rs9608099        
AD 1005 96 (0.096) 459 (0.457) 450 (0.448) 0.354 0.324 0.676 0.319 
C 996 96 (0.096) 424 (0.426) 476 (0.478) 0.309 0.691 
     n         CC                       CT                       TT p    C             T   p 
SNP10 
MYH13 
rs2074877        
AD 1009 408 (0.214) 458 (0.495) 143 (0.291) 0.931 0.462 0.538 0.955 
C 1004 381 (0.211) 493 (0.503) 130 (0.286) 0.463 0.537 
     n         CC                       CT                        TT    p    C             T    p 
SNP11 
EBF3   
rs11016976      
AD 1009 24 (0.024) 252 (0.250) 733 (0.726) 0.354 0.149 0.851 0.192 
C 1005 23 (0.023) 224 (0.223) 758 (0.754) 0.134 0.866 
     n        AA                        CA                       CC    p   A             C    p 
SNP12 
AGC1 
rs2882676        
AD 107 145 (0.144) 455 (0.452) 407 (0.404) 0.674 0.370 0.630 0.476 
C 997 130 (0.130) 456 (0.457) 411 (0.412) 0.359 0.641 
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Table 3.3 continued: 
     n        AA                        AG                      GG    p   A             G    p 
SNP13 
CTSS 
       
AD 1009 859 (0.851) 142 (0.141) 8 (0.008) 0.121 0.922 0.078 0.924 
C 1005 848 (0.844) 155 (0.154) 2 (0.002) 0.921 0.079 
     n         AA                       AT                       TT p    A             T    p 
SNP14 
FAM63A 
          
AD 1008 6 (0.006) 117 (0.116) 885 (0.878) 0.059 0.064 0.936 0.924 
C 1007 1 (0.001) 139 (0.138) 867 (0.861) 0.070 0.930 
     n         CC                        CT                       TT    p    C             T    p 
SNP15 
TRAK2  
rs13022344      
AD 1009 108 (0.107) 457 (0.453) 444 (0.440) 0.912 0.333 0.667 0.797 
C 1001 108 (0.108) 444 (0.444) 449 (0.449) 0.330 0.670 
     n         AA                       AG                      GG    p   A             G    p 
SNP16   
rs6907175       
AD 967 266 (0.275) 435 (0.450) 266 (0.275) 0.061 0.500 0.500 0.542 
C 969 251 (0.259) 486 (0.502) 232 (0.239) 0.510 0.490 
     n         CC                        CT                       TT    p   C             T    p 
SNP17 
rs501120       
AD 1008 19 (0.019) 260 (0.258) 729 (0.723) 0.899 0.148 0.852 0.688 
C 1008 19 (0.019) 251 (0.249) 738 (0.732) 0.143 0.857 
     n        AA                        AC                       CC p    A             C    p 
SNP18 
rs2943634       
AD 1000 127 (0.127) 431 (0.431) 442 (0.442) 0.793 0.343 0.658 0.497 
C 996 118 (0.118) 426 (0.428) 452 (0.454) 0.332 0.668 
     n        CC                        CT                       TT    p    C             T    p 
SNP19 
SMAD3 
rs17228212      
AD 1009 76 (0.075) 376 (0.373) 557 (0.552) 0.945 0.262 0.738 0.954 
C 1004 79 (0.079) 369 (0.368) 556 (0.554) 0.262 0.738 
     n        CC                        CG                     GG    p   C             G    p 
SNP20 
rs1333049        
AD 1009 251 (0.249) 492 (0.488) 266 (0.264) 0.201 0.493 0.507 0.704 
C 1007 225 (0.223) 530 (0.526) 252 (0.250) 0.487 0.513 
     n        AA                        AG                    GG    p   A             G    p 
SNP21 
MTHRD1L 
rs6922269       
AD 1008 75 (0.074) 395 (0.392) 538 (0.534) 0.704 0.270 0.729 0.414 
C 1004 67 (0.067) 386 (0.384) 551 (0.549) 0.259 0.742 
     n         CC                        CT                     TT p    C             T    p 
SNP22 
TCF7L2 
rs7901695        
AD 1009 95 (0.094) 423 (0.419) 491 (0.487) 0.282 0.304 0.696 0.125 
C 1007 114 (0.113) 429 (0.426) 464 (0.461) 0.326 0.674 
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3.5 STRATIFICATION BY APOE 
 
APOE stratified data for 22 SNPs are presented in Table 3.4.  Among non-APOE*4 carriers, 3 
significant association were observed.  SNP3 TNK1/rs1554948 showed a significant difference in 
genotypes (p=0.029) and allele frequencies (p=0.017) between cases and controls. SNP7 
UBD/rs444013 (p=0.044) and SNP18 rs2943634 (p=0.039) showed a significant difference in 
allele frequencies.  SNP16 rs6907175 showed a significant difference in genotype frequencies 
(p=0.032).  Among APOE*4 carriers, SNP2 PCK1/rs8192708 showed a significant difference in 
genotype frequencies (p=0.018). 
 
Table 3.4. Distribution of 22 SNPs, based on APOE*4 carriers and non APOE*4 carriers 
       Genotype  n (%)              Allele  
      n           CC                      CG                    GG    p   C             G    p 
SNP1 
GALP 
rs3745833        
No 
E4 
AD 427 169 (0.396) 198 (0.464) 60 (0.141) 0.948 0.628 0.372 0.782 
C 799 320 (0.401) 372 (0.466) 107 (0.134) 0.633 0.367 
E4 AD 580 257 (0.443) 267 (0.460) 56 (0.097) 0.535 0.673 0.327 0.276 
C 202 81 (0.401) 98 (0.485) 23 (0.114) 0.644 0.356 
      n           AA                      AG                    GG    p   A            G    p 
SNP2 
PCK1   
rs8192708        
No 
E4 
AD 427 332 (0.778) 68 (0.159) 27 (0.063) 0.629 0.857 0.143 0.285 
C 801 608 (0.759) 131 (0.164) 62 (0.077) 0.841 0.159 
E4 AD 581 475 (0.818) 70 (0.120) 36 (0.062) 0.018 0.878 0.122 0.097 
C 204 152 (0.745) 41 (0.201) 11 (0.054) 0.846 0.154 
      n           AA                      AT                     TT    p   A            T    p 
SNP3 
TNK1 
rs1554948        
No 
E4 
AD 427 67 (0.157) 212 (0.496) 148 (0.347) 0.029 0.405 0.595 0.017 
C 798 175 (0.219) 377 (0.472) 246 (0.308) 0.456 0.544 
E4 AD 581 119 (0.205) 293 (0.504) 169 (0.291) 0.568 0.457 0.543 0.515 
C 205 49 (0.239) 97 (0.473) 59 (0.288) 0.476 0.524 
      n           AA                      AT                     TT    p   A            T    p 
SNP4 
SERPINA13 
rs11622883      
No 
E4 
AD 426 88 (0.207) 230 (0.540) 108 (0.254) 0.270 0.477 0.523 0.485 
C 797 171 (0.215) 394 (0.494) 232 (0.291) 0.462 0.538 
E4 AD 580 128 (0.221) 268 (0.462) 184(0.317) 0.203 0.452 0.548 0.688 
C 204 40 (0.196) 109 (0.534) 55 (0.270) 0.463 0.537 
      n           AA                      GA                    GG    p   A            G    p 
SNP5 
PGBD1   
No 
E4 
AD 427 0 (0.000) 44 (0.103) 383 (0.897) 0.132 0.052 0.948 0.282 
C 797 3 (0.004) 61 (0.077) 733 (0.920) 0.042 0.958 
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rs3800324        E4 AD 581 0 (0.000) 40 (0.069) 541 (0.931)  0.034 0.966 0.629 
C 202 0 (0.000) 16 (0.079) 186 (0.921) 0.040 0.960 
      n           CC                       CT                     TT    p   C             T    p 
SNP6 
LAMIN AC 
rs505058          
No 
E4 
AD 427 7 (0.016) 71 (0.166) 349 (0.817) 0.416 0.100 0.900 0.974 
C 797 7 (0.009) 144 (0.181) 646 (0.811) 0.099 0.901 
E4 AD 581 9 (0.015) 102 (0.176) 470 (0.809) 0.441 0.103 0.897 0.190 
C 204 2 (0.010) 29 (0.142) 173 (0.848) 0.081 0.919 
      n           CC                      CG                     GG    p   C             G    p 
SNP7 
UBD  
rs444013       
No 
E4 
AD 427 104 (0.244) 215 (0.504) 108 (0.253) 0.108 0.495 0.505 0.044 
C 790 236 (0.299) 378 (0.478) 176 (0.223) 0.538 0.462 
E4 AD 581 150 (0.258) 310 (0.534) 121 (0.208) 0.132 0.525 0.475 0.789 
C 203 59 (0.291) 92 (0.453) 52 (0.256) 0.517 0.483 
      n           CC                      CG                     GG    p   C             G    p 
SNP8 
rs1859849  
  
No 
E4 
AD 427 24 (0.056) 167 (0.391) 236 (0.553) 0.372 0.252 0.748 0.596 
C 797 61 (0.077) 295 (0.370) 441 (0.553) 0.262 0.738 
E4 AD 581 35 (0.060) 222 (0.382) 324 (0.558) 0.718 0.251 0.749 0.923 
C 203 15 (0.074) 73 (0.360) 115 (0.567) 0.254 0.746 
      n           CC                      TC                      TT    p   C            T    p 
SNP9 
BCR 
rs9608099        
No 
E4 
AD 426 43 (0.101) 193 (0.453) 190 (0.446) 0.420 0.327 0.673 0.244 
C 793 75 (0.095) 333 (0.420) 385 (0.485) 0.305 0.695 
E4 AD 578 53 (0.092) 266 (0.460) 259 (0.448) 0.855 0.322 0.678 0.763 
C 2000 21 (0.105) 90 (0.450) 89 (0.445) 0.330 0.670 
      n           CC                      CT                      TT    p   C             T    p 
SNP10 
MYH13 
rs2074877        
No 
E4 
AD 427 172 (0.403) 199 (0.466) 56 (0.131) 0.810 0.636 0.364 0.550 
C 797 306 (0.384) 382 (0.479) 109 (0.137) 0.624 0.376 
E4 AD 581 236 (0.406) 258 (0.444) 87 (0.150) 0.034 0.628 0.372 0.934 
C 203 73 (0.360) 110 (0.542) 20 (0.099) 0.631 0.369 
      n            CC                     TC                      TT    p   C             T    p 
SNP11 
EBF3   
rs11016976      
No 
E4 
AD 427 10 (0.023) 113 (0.265) 304 (0.712) 0.387 0.156 0.844 0.247 
C 798 19 (0.024) 183 (0.229) 596 (0.747) 0.138 0.862 
E4 AD 581 14 (0.024) 139 (0.239) 428 (0.737) 0.481 0.144 0.856 0.233 
C 204 4 (0.020) 41 (0.201) 159 (0.779) 0.120 0.880 
      n           AA                      CA                     CC    p   A            C    p 
SNP12 
AGC1 
rs2882676        
  
No 
E4 
AD 427 64 (0.150) 199 (0.466) 164 (0.384) 0.326 0.383 0.617 0.136 
C 793 104 (0.131) 351 (0.443) 338 (0.426) 0.352 0.648 
E4 AD 579 81 (0.140) 256 (0.442) 242 (0.418) 0.218 0.361 0.639 0.378 
C 201 26 (0.129) 103 (0.512) 72 (0.358) 0.386 0.614 
      n           AA                      AG                    GG    p   C             G    p 
SNP13 
CTSS 
  
No 
E4 
AD 427 365 (0.855) 57 (0.133) 5 (0.012) 0.091 0.922 0.078 0.998 
C 797 674 (0.846) 121 (0.152) 2 (0.003) 0.922 0.078 
E4 AD 581 493 (0.849) 85 (0.146) 3 (0.005) 0.471 0.922 0.078 0.747 
C 204 170 (0.833) 34 (0.167) 0 (0.000) 0.917 0.083 
      n           AA                      TA                     TT    p   A             T    p 
SNP14 
FAM63A 
  
No 
E4 
AD 426 3 (0.007) 50 (0.117) 373 (0.876) 0.158 0.066 0.934 0.727 
C 799 1 (0.001) 109 (0.136) 689 (0.862) 0.069 0.931 
E4 AD 581 3 (0.005) 67 (0.115) 511 (0.880) 0.300 0.063 0.937 0.452 
C 204 0(0.000) 30 (0.147) 174 (0.853) 0.074 0.926 
      n           CC                       TC                     TT    p   C             T    p 
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SNP15 
TRAK2  
rs13022344      
No 
E4 
AD 427 48 (0.112) 199 (0.466) 180 (0.422) 0.678 0.345 0.655 0.492 
C 796 88 (0.111) 352 (0.442) 356 (0.447) 0.332 0.668 
E4 AD 581 60 (0.103) 258 (0.444) 263 (0.453) 0.957 0.325 0.675 0.958 
C 202 20 (0.099) 92 (0.455) 90 (0.446) 0.327 0.673 
      n           AA                       AG                    GG    p   A             G    p 
SNP16  
rs6907175 
  
No 
E4 
AD 412 106 (0.257) 181 (0.439) 125 (0.303) 0.032 0.477 0.523 0.084 
C 776 205 (0.264) 388 (0.500) 183 (0.236) 0.514 0.486 
E4 AD 554 160 (0.289) 253 (0.457) 141 (0.255) 0.299 0.517 0.483 0.352 
C 192 45 (0.234) 98 (0.510) 49 (0.255) 0.490 0.510 
      n            CC                      CT                      TT    p   C             T    p 
SNP17 
rs501120  
No 
E4 
AD 427 6 (0.014) 108 (0.253) 313 (0.733) 0.742 0.141 0.859 0.587 
C 804 16 (0.020) 207 (0.257) 581 (0.723) 0.149 0.851 
E4 AD 580 13 (0.022) 152 (0.262) 415 (0.716) 0.310 0.153 0.847 0.128 
C 204 3 (0.015) 44 (0.216) 157 (0.770) 0.123 0.877 
      n           AA                      CA                      CC    p   A             C    p 
SNP18 
rs2943634  
No 
E4 
AD 425 56 (0.132) 179 (0.421) 190 (0.447) 0.701 0.342 0.658 0.967 
C 794 96 (0.121) 353 (0.445) 345 (0.435) 0.343 0.657 
E4 AD 574 71 (0.124) 251 (0.437) 252 (0.439) 0.074 0.342 0.658 0.039 
C 201 21 (0.104) 73 (0.363) 107 (0.532) 0.286 0.714 
      n           CC                       TC                     TT    p   C             T    p 
SNP19 
SMAD3 
rs17228212  
No 
E4 
AD 427 26 (0.061) 153 (0.358) 248 (0.581) 0.434 0.240 0.760 0.218 
C 801 63 (0.079) 295 (0.368) 443 (0.553) 0.263 0.737 
E4 AD 581 50 (0.086) 223 (0.384) 308 (0.530) 0.803 0.278 0.722 0.511 
C 203 16 (0.079) 74 (0.365) 113 (0.557) 0.261 0.739 
      n            CC                      GC                    GG    p   C             G    p 
SNP20 
rs1333049  
No 
E4 
AD 427 106 (0.248) 215 (0.504) 106 (0.248) 0.633 0.500 0.500 0.480 
C 803 180 (0.224) 419 (0522) 204 (0.254) 0.485 0.515 
E4 AD 581 144 (0.248) 277 (0.477) 160 (0.275) 0.251 0.486 0.514 0.823 
C 204 45 (0.221) 111 (0.544) 48 (0.235) 0.493 0.507 
      n          AA                       AG                    GG    p   A             G    p 
SNP21 
MTHRD1L 
rs6922269  
No 
E4 
AD 427 30 (0.070) 171 (0.400) 226 (0.529) 0.688 0.270 0.730 0.444 
C 800 54 (0.068) 302 (0.378) 444 (0.555) 0.256 0.744 
E4 AD 580 44 (0.076) 224 (0.386) 312 (0.538) 0.723 0.269 0.731 0.939 
C 203 13 (0.064) 84 (0.414) 106 (0.522) 0.271 0.729 
      n           CC                       CT                     TT    p   C             T    p 
SNP22 
TCF7L2 
rs7901695 
  
No 
E4 
AD 427 46 (0.108) 173 (0.405) 208 (0.487) 0.641 0.310 0.690 0.351 
C 803 94 (0.117) 340 (0.423) 369 (0.460) 0.329 0.671 
E4 AD 581 49 (0.084) 250 (0.430) 282 (0.485) 0.796 0.299 0.701 0.528 
C 204 20 (0.098) 89 (0.436) 95 (0.466) 0.316 0.684 
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3.6 STRATIFICATION BY AUTOPSY VS CLINICAL 
Autopsy confirmed cases vs clinically diagnosed cases were stratified for 22 SNPs, the data is 
presented in Table 3.5.  The analysis did not reveal any SNPs with statistically significant 
difference. The Alzheimer’s Disease Research Center has found a high correlation (>95%) 
between clinically diagnosed AD cases and those confirmed at autopsy.  This 5% uncertainty 
may explain the inability of our study to detect a significant difference in cases diagnosed by 
autopsy vs clinically. 
 
Table 3.5. Distribution of 22 SNPs, based on autopsy vs clinical diagnosis in cases 
      Genotype n (%)   Allele  
       n CC CG GG    p   C G    p 
SNP1 AUT 79 40(0.506) 29(0.367) 10(0.127) 0.202 0.69 0.31 0.32 
GALP   CLIN 929 386(0.416) 437(0.470) 106(0.114)   0.651 0.349   
SNP2      n AA AG GG p A G p 
PCK1   AUT 79 64(0.810) 14(0.177) 1(0.013) 0.112 0.899 0.101 0.244 
rs8192708          CLIN 930 743(0.799) 125(0.134) 62(0.067)   0.866 0.134   
SNP3      n AA AT TT p A T p 
TNK1 AUT 79 14(0.177) 44(0.577) 21(0.266) 0.545 0.456 0.544 0.595 
rs1554948          CLIN 930 173(0.186) 461(0.496) 296(0.318)   0.434 0.566   
SNP4      n AA AT TT p A T p 
SERPINA13 AUT 79 21(0.266) 29(0.367) 29(0.367) 0.062 0.449 0.551 0.745 
rs11622883         CLIN 928 195(0.210) 469(0.505) 264(0.284)   0.463 0.537   
SNP5      n AA GA GG p A G p 
PGBD1   AUT 79 0(0.000) 7(0.089) 72(0.911) N/A 0.044 0.956 0.861 
rs3800324          CLIN 930 0(0.000) 77(0.083) 853(0.917)   0.041 0.959   
SNP6      n CC CT TT p C T p 
LAMIN AC AUT 79 0(0.000) 11(0.139) 68(0.861) 0.346 0.07 0.93 0.168 
rs505058          CLIN 930 16(0.017) 162(0.74) 752(0.809)   0.104 0.896   
SNP7      n CC CG GG p C G p 
UBD  AUT 79 20(0.253) 43(0.544) 16(0.203) 0.852 0.525 0.475 0.745 
rs444013       CLIN 930 235(0.253) 482(0.518) 213(0.229)   0.512 0.488   
SNP8      n CC CG GG p C G p 
rs1859849  AUT 79 6(0.076) 27(0.342) 46(0.582) 0.613 0.247 0.753 0.894 
  CLIN 930 53(0.057) 362(0.389) 515(0.554)   0.252 0.748   
SNP9      n CC TC TT p C T p 
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BCR AUT 78 6(0.077) 34(0.436) 38(0.487) 0.712 0.295 0.705 0.42 
rs9608099        CLIN 927 90(0.097) 425(0.458) 412(0.444)   0.326 0.674   
SNP10      n CC CT TT p C T p 
MYH13 AUT 79 25(0.316) 42(0.532) 12(0.152) 0.242 0.582 0.418 0.183 
rs2074877          CLIN 930 383(0.412) 416(0.447) 131(0.141)   0.635 0.365   
SNP11      n CC TC TT p C T p 
EBF3   AUT 79 3(0.038) 21(0.266) 55(0.696) 0.631 0.171 0.829 0.413 
rs11016976         CLIN 930 21(0.023) 231(0.248) 678(0.729)   0.147 0.853   
SNP12      n AA CA CC p A C p 
AGC1 AUT 79 8(0.101) 41(0.519) 30(0.380) 0.355 0.361 0.639 0.804 
rs2882676           CLIN 928 137(0.148) 414(0.446) 377(0.406)   0.371 0.629   
SNP13      n AA AG GG p A G p 
CTSS AUT 79 68(0.861) 11(0.139) 0(0.000) 0.708 0.93 0.07 0.672 
  CLIN 930 791(0.851) 131(0.141) 8(0.009)   0.921 0.079   
SNP14 
FAM63A 
     n AA TA TT p A T p 
AUT 79 0(0.000) 8(0.101) 71(0.899) 0.7 0.051 0.949 0.475 
 CLIN 929 6(0.006) 109(0.117) 814(0.876)   0.065 0.935   
 SNP15 
TRAK2 
     n CC TC TT p C T p 
AUT 79 6(0.076) 39(0.494) 34(0.430) 0.575 0.323 0.677 0.766 
 CLIN 930 102(0.110) 418(0.449) 410(0.441)   0.334 0.666   
 SNP16 
rs6907175 
     n AA AG GG p A G p 
AUT 75 21(0.280) 32(0.427) 22(0.293) 0.904 0.493 0.507 0.865 
 CLIN 892 245(0.275) 403(0.452) 244(0.274)   0.501 0.499   
SNP17  
rs501120 
     n CC CT TT p C T p 
AUT 79 0(0.000) 27(0.342) 52(0.658) 0.108 0.171 0.829 0.395 
 CLIN 929 19(0.020) 233(0.251) 677(0.729)   0.146 0.854   
SNP18 
rs2943634 
     n AA CA CC p A C p 
AUT 78 14(0.179) 27(0.346) 37(0.474) 0.178 0.353 0.647 0.783 
 CLIN 922 113(0.123) 404(0.438) 405(0.439)   0.342 0.658   
 SNP19 
SMAD3 
     n CC TC TT p C T p 
AUT 79 1(0.013) 30(0.380) 48(0.608) 0.084 0.203 0.797 0.078 
rs17228212  CLIN 930 75(0.081) 346(0.372) 509(0.547)   0.267 0.733   
 SNP20 
rs1333049 
     n CC GC GG p C G p 
AUT 79 22(0.278) 31(0.392) 26(0.329) 0.193 0.475 0.525 0.64 
 CLIN 930 229(0.246) 461(0.496) 240(0.258)   0.494 0.506   
 SNP21 
MTHRD1L 
     n AA AG GG p A G p 
AUT 79 5(0.063) 27(0.342) 47(0.595) 0.524 0.234 0.766 0.286 
rs6922269 CLIN 929 70(0.075) 368(0.396) 491(0.529)   0.273 0.727   
SNP22 
TCF7L2 
rs7901695 
     n CC CT TT p C T p 
AUT 79 6(0.076) 30(0.380) 43(0.544) 0.547 0.266 0.734 0.28 
 CLIN 930 89(0.096) 393(0.423) 448(0.482)   0.307 0.693   
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 3.7 AGE STRATIFIED ANALYSIS 
In order to examine a possible affect of age we stratified the data in to three age groups: 60-69, 
70-79 and >80 years of age (Table 3.6).  The cases were categorized by AAO, and the controls 
were categorized by the age at which they were brought into the study.  SNP2 PCK1/ rs8192708 
showed a statistically significant difference in allele frequency between cases and controls in the 
>80 age group (p=0.012).  SNP3 TNK1/rs1554948 showed a statistically significant difference in 
genotype frequencies between cases and controls in the 70-79 age group (p=0.024).  SNP10 
MYH13/rs2074877 showed a statistically significant difference in genotype frequencies between 
cases and controls in the >80 age group (p=0.008).  SNP12 AGC1/rs2882676 showed a 
statistically significant difference in allele frequencies between cases and controls in the >80 age 
group (p=0.036).  SNP21 MTHRD1L/rs6922269 showed a statistically significant difference in 
allele frequencies between cases and controls in the 60-69 age group (p=0.023).   
 
Table 3.6. 22 SNPs stratified by three age groups 
       Genotype  n (%)              Allele  
      n          CC                   CG                  GG    p   C            G    p 
 
SNP1 
GALP   
rs3745833        
60-69 AD 301 128(0.425) 141(0.468) 32(0.106) 0.508 0.659 0.341 0.260 
C 230 87(0.378) 114(0.496) 29(0.126) 0.626 0.374 
70-79 AD 526 218(0.414) 243(0.462) 65(0.124) 0.989 0.645 0.355 0.908 
C 601 248(0.413) 277(0.461) 76(0.126) 0.643 0.357 
>80 AD 143 67(0.469) 60(0.420) 16(0.112) 0.225 0.678 0.322 0.102 
C 169 63(0.373) 82(0.485) 24(0.142) 0.615 0.385 
      n         AA                   AG                  GG    p   A            G    p 
 
SNP2 
PCK1   
rs8192708        
60-69 AD 302 245(0.811) 40(0.132) 17(0.056) 0.291 0.877 0.123 0.134 
C 230 174(0.757) 41(0.178) 15(0.065) 0.846 0.154 
70-79 AD 526 414(0.787) 72(0.137) 40(0.076) 0.422 0.856 0.144 0.617 
C 602 461(0.766) 99(0.164) 42(0.070) 0.848 0.152 
>80 AD 143 116(0.811) 22(0.154) 5(0.035) 0.084 0.888 0.112 0.012 
C 171 123(0.719) 33(0.193) 15(0.088) 0.816 0.184 
      n AA         AT            TT    p   A              T    p 
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SNP3 
TNK1 
rs1554948        
60-69 AD 302 65(0.215) 143(0.474) 94(0.311) 0.485 0.452 0.548 0.828 
C 230 45(0.196) 121(0.526) 64(0.278) 0.459 0.541 
70-79 AD 526 91(0.173) 280(0.532) 155(0.295) 0.024 0.439 0.561 0.204 
C 601 140(0.233) 280(0.466) 181(0.301) 0.466 0.534 
>80 AD 413 22(0.154) 68(0.476) 53(0.371) 0.191 0.392 0.608 0.185 
C 170 40(0.235) 71(0.418) 59(0.347) 0.444 0.556 
      n AA          AT          TT    p   A            T    p 
 
SNP4 
SERPINA13 
rs11622883      
60-69 AD 302 61(0.202) 143(0.474) 98(0.325) 0.652 0.439 0.561 0.517 
C 230 54(0.235) 103(0.448) 73(0.317) 0.459 0.541 
70-79 AD 524 117(0.223) 262(0.500) 145(0.277) 0.622 0.473 0.527 0.529 
C 600 120(0.200) 312(0.520) 168(0.280) 0.460 0.540 
>80 AD 143 28(0.196) 78(0.545) 38(0.259) 0.770 0.469 0.531 0.789 
C 169 38(0.225) 86(0.509) 45(0.266) 0.479 0.521 
      n AA            AG          GG    p   A            G    p 
 
SNP5 
PGBD1   
rs3800324        
60-69 AD 302 0(0.000) 18(0.060) 284(0.940) 0.137 0.030 0.970 0.310 
C 230 3(0.013) 13(0.057) 214(0.930) 0.041 0.959 
70-79 AD 526 0(0.000) 52(0.099) 474(0.901) 0.469 0.049 0.951 0.437 
C 599 0(0.000) 51(0.085) 548(0.915) 0.043 0.957 
>80 AD 143 0(0.000) 11(0.077) 132(0.923) 1.000 0.038 0.962 0.856 
C. 168 0(0.000) 12(0.071) 156(0.929) 0.036 0.964 
      n AA            AG          GG    p   A            G    p 
 
SNP6 
LAMIN AC 
rs505058          
60-69 AD 302 6(0.020) 55(0.182) 241(0.798) 0.214 0.111 0.889 0.074 
C 230 3(0.013) 30(0.130) 197(0.857) 0.078 0.922 
70-79 AD 526 8(0.015) 90(0.171) 428(0.814) 0.480 0.101 0.899 0.647 
C 600 6(0.010) 116(0.193) 478(0.797) 0.107 0.893 
>80 AD 143 2(0.014) 23(0.161) 118(0.825) 0.746 0.094 0.906 0.596 
C 170 1(0.006) 26(0.153) 143(0.841) 0.082 0.918 
      n CC            CG          GG    p   C            G    p 
 
SNP7 
UBD  
rs444013       
60-69 AD 302 77(0.255) 161(0.533) 64(0.212) 0.213 0.522 0.478 0.152 
C 228 74(0.325) 110(0.482) 44(0.193) 0.566 0.434 
70-79 AD 526 134(0.255) 272(0.517) 120(0.228) 0.278 0.513 0.487 0.572 
C 594 172(0.290) 280(0.471) 142(0.239) 0.525 0.475 
>80 AD 143 34(0.238) 72(0.503) 37(0.259) 0.647 0.490 0.510 0.482 
C 169 48(0.284) 79(0.467) 42(0.249) 0.518 0.482 
      n CC            CG          GG    p   C            G    p 
 
SNP8 
rs1859849  
 
60-69 AD 302 14(0.046) 111(0.368) 177(0.586) 0.905 0.230 0.770 0.943 
C 230 9(0.039) 87(0.378) 134(0.583) 0.228 0.772 
70-79 AD 526 35(0.067) 207(0.394) 284(0.540) 0.600 0.263 0.737 0.896 
C 598 46(0.077) 220(0.368) 332(0.555) 0.261 0.739 
>80 AD 143 7(0.049) 60(0.420) 76(0.531) 0.061 0.259 0.741 0.221 
C 170 21(0.124) 61(0.359) 88(0.518) 0.303 0.697 
      n CC            TC          TT    p   C            T    p 
 
SNP9 
BCR 
rs9608099        
60-69 AD 300 25(0.083) 140(0.467) 135(0.450) 0.851 0.317 0.683 0.882 
C 229 22(0.096) 103(0.450) 104(0.454) 0.321 0.679 
70-79 AD 525 52(0.099) 232(0.442) 241(0.459) 0.906 0.320 0.680 0.715 
C 593 58(0.098) 255(0.430) 280(0.472) 0.313 0.687 
>80 AD 143 15(0.159) 71(0.497) 57(0.399) 0.091 0.353 0.647 0.077 
C 169 16(0.095) 65(0.385) 88(0.521) 0.287 0.713 
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      n CC            CT          TT    p   C            T    p 
 
SNP10 
MYH13 
rs2074877        
60-69 AD 302 126(0.417) 145(0.480) 31(0.103) 0.235 0.657 0.343 0.106 
C 229 83(0.362) 113(0.490) 33(0.144) 0.609 0.391 
70-79 AD 526 206(0.392) 247(0.471) 73(0.139) 0.908 0.626 0.374 0.696 
C 599 239(0.399) 282(0.471) 78(0.130) 0.634 0.366 
>80 AD 143 57(0.399) 56(0.392) 30(0.210) 0.008 0.594 0.406 0.616 
C 171 58(0.339) 94(0.550) 19(0.111) 0.614 0.386 
      n CC            CT          TT    p   C            T    p 
 
SNP11 
EBF3   
rs11016976      
60-69 AD 302 8(0.026) 79(0.262) 215(0.712) 0.442 0.157 0.843 0.260 
C 230 3(0.013) 55(0.239) 172(0.748) 0.133 0.867 
70-79 AD 526 10(0.019) 130(0.240) 386(0.734) 0.142 0.143 0.857 0.498 
C 599 18(0.030) 123(0.205) 458(0.765) 0.133 0.867 
>80 AD 143 4(0.028) 40(0.280) 99(0.692) 0.551 0.168 0.832 0.457 
C 171 2(0.012) 46(0.269) 123(0.719) 0.146 0.854 
      n AA            AC          CC    p   A            C    p 
 
SNP12 
AGC1 
rs2882676        
60-69 AD 301 41(0.136) 141(0.468) 119(0.395) 0.912 0.370 0.630 0.846 
C 229 32(0.140) 103(0.450) 94(0.410) 0.365 0.635 
70-79 AD 525 73(0.139) 234(0.446) 218(0.415) 0.889 0.362 0.638 0.756 
C 592 82(0.139) 272(0.459) 238(0.402) 0.368 0.632 
>80 AD 143 26(0.182) 63(0.441) 54(0.378) 0.062 0.402 0.598 0.036 
C 171 16(0.094) 78(0.456) 77(0.450) 0.322 0.678 
      n AA            AG          GG    p   A            G    p 
 
SNP13 
CTSS 
 
60-69 AD 302 255(0.844) 46(0.152) 1(0.003) 0.903 0.921 0.079 0.661 
C 230 191(0.830) 38(0.165) 1(0.004) 0.913 0.087 
70-79 AD 526 446(0.848) 74(0.141) 6(0.011) 0.082 0.918 0.082 0.994 
C 600 503(0.838) 96(0.160) 1(0.002) 0.918 0.082 
>80 AD 143 125(0.874) 17(0.119) 1(0.007) 0.550 0.934 0.066 0.695 
C 170 150(0.882) 20(0.118) 0(0.000) 0.941 0.059 
      n AA            AT          TT    p   A              T    p 
 
SNP14 
FAM63A 
60-69 AD 302 0(0.000) 37(0.123) 265(0.877) 0.470 0.061 0.939 0.495 
C 230 1(0.040) 31(0.135) 198(0.861) 0.072 0.928 
70-79 AD 525 5(0.010) 62(0.118) 458(0.872) 0.037 0.069 0.931 0.973 
C 602 0(0.000) 83(0.138) 519(0.862) 0.069 0.931 
>80 AD 143 1(0.007) 14(0.098) 128(0.895) 0.286 0.056 0.944 0.456 
C 170 0(0.000) 24(0.141) 146(0.859) 0.071 0.929 
      n CC            TC          CC    p   C            T    p 
 
SNP15 
TRAK2  
rs13022344      
60-69 AD 302 30(0.099) 143(0.474) 129(0.427) 0.437 0.336 0.664 0.211 
C 230 18(0.078) 102(0.443) 110(0.478) 0.300 0.700 
70-79 AD 526 59(0.112) 236(0.449) 231(0.439) 0.536 0.337 0.668 0.671 
C 599 72(0.120) 249(0.416) 278(0.464) 0.328 0.672 
>80 AD 143 16(0.112) 60(0.420) 67(0.469) 0.091 0.322 0.678 0.149 
C 167 18(0.108) 90(0.539) 59(0.353) 0.377 0.623 
      n AA            AG          GG    p   A            G    p 
 
SNP16  
rs6907175 
60-69 AD 115 37(0.322) 50(0.435) 28(0.243) 0.453 0.539 0.461 0.674 
C 226 61(0.270) 114(0.504) 51(0.226) 0.522 0.478 
70-79 AD 512 145(0.283) 227(0.443) 140(0.273) 0.302 0.505 0.495 0.981 
C 571 148(0.259) 280(0.490) 143(0.250) 0.504 0.496 
>80 AD 340 84(0.247) 158(0.465) 98(0.288) 0.155 0.479 0.521 0.330 
Table 3.6 continued:  
 33 
Table 3.6 continued:  
C 167 40(0.240) 91(0.545) 36(0.216) 0.512 0.488 
      n CC            CT          TT    p   C            T    p 
 
SNP17 
rs501120 
60-69 AD 121 4(0.033) 32(0.264) 85(0.702) 0.248 0.165 0.835 0.348 
C 227 2(0.009) 59(0.260) 166(0.731) 0.139 0.861 
70-79 AD 530 8(0.015) 128(0.242) 394(0.743) 0.732 0.136 0.864 0.965 
C 588 12(0.020) 135(0.230) 441(0.750) 0135 0.865 
>80 AD 343 7(0.020) 94(0.274) 242(0.706) 0.771 0.157 0.843 0.537 
C 171 5(0.029) 49(0.287) 117(0.684) 0.173 0.827 
      n AA          AC           CC    p   A              C    p 
 
SNP18 
rs2943634 
60-69 AD 115 9(0.078) 52(0.4520 54(0.470) 0.323 0.304 0.696 -.929 
C 221 26(0.118) 84(0.380) 111(0.502) 0.308 0.692 
70-79 AD 507 74(0.146) 209(0.412) 224(0.442) 0.301 0.352 0.648 0.264 
C 577 66(0.114) 248(0.430) 263(0.456) 0.329 0.671 
>80 AD 330 40(0.121) 144(0.430) 146(0.442) 0.742 0.339 0.661 0.508 
C 165 21(0.127) 77(0.467) 67(0.406) 0.361 0.639 
      n CC            CT          TT    p   C            T    p 
 
SNP19 
SMAD3 
rs17228212 
60-69 AD 121 12(0.099) 46(0.380) 63(0.521) 0.982 0.289 0.711 0.947 
C 228 22(0.096) 89(0.390) 117(0.513) 0.292 0.708 
70-79 AD 526 42(0.080) 196(0.373) 288(0.548) 0.656 0.266 0.734 0.348 
C 583 41(0.070) 208(0.357) 334(0.573) 0.249 0.751 
>80 AD 344 21(0.061) 128(0.372) 195(0.567) 0.962 0.247 0.753 0.957 
C 169 11(0.065) 61(0.361) 97(0.574) 0.246 0.754 
      n AA            AG          GG    p   A            G    p 
 
SNP20 
rs1333049 
60-69 AD 120 23(0.192) 60(0.500) 37(0.308) 0.712 0.442 0.558 0.419 
C 229 50(0.218) 117(0.511) 62(0.271) 0.474 0.526 
70-79 AD 532 133(0.250) 259(0.487) 140(0.263) 0.215 0.493 0.507 0.518 
C 593 126(0.212) 317(0.535) 150(0.253) 0.480 0.520 
>80 AD 338 91(0.269) 161(0.476) 86(0.254) 0.545 0.507 0.493 0.404 
C 171 48(0.281) 87(0.509) 36(0.211) 0.535 0.465 
      n AA            AG          GG    p   A            G    p 
 
SNP21 
MTHRD1L 
rs6922269 
60-69 AD 118 11(0.093) 52(0.441) 55(0.466) 0.063 0.314 0.686 0.023 
C 229 15(0.066) 77(0.336) 137(0.598) 0.234 0.766 
70-79 AD 528 43(0.081) 211(0.4000 274(0.519) 0.795 0.281 0.719 0.505 
C 590 43(0.073) 231(0.392) 316(0.536) 0.269 0.731 
>80 AD 340 18(0.053) 127(0.374) 195(0.574) 0.573 0.240 0.760 0.681 
C 167 7(0.042) 70(0.419) 90(0.539) 0.251 0.749 
      n AA            AG          GG    p   A            G    p 
 
SNP22 
TCF7L2 
rs7901695 
60-69 AD 122 10(0.0820 52(0.426) 60(0.492) 0.751 0.295 0.705 0.869 
C 230 22(0.096) 89(0.387) 119(0.517) 0.289 0.711 
70-79 AD 528 53(0.100) 224(0.424) 251(0.475) 0.562 0.313 0.688 0.280 
C 593 68(0.115) 260(0.438) 265(0.447) 0.334 0.666 
>80 AD 341 32(0.094) 136(0.399) 173(0.507) 0.290 0.293 0.707 0.112 
C 168 22(0.131) 71(0.423) 75(0.446) 0.342 0.658 
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3.8 ANALYSIS OF VARIANCE OF 22 SNPS FOR AGE-AT-ONSET (AAO) 
APOE-adjusted mean value of AAO among AD cases for each SNP are given in Table 3.7.  
Analysis of variance (ANOVA) was used in order to determine if the mean of a variable was 
significantly different between genotypes.  The ANOVA calculation for AAO showed a 
statistically significant difference between genotypes for SNP10 MYH13/rs2074877 (p=0.00196) 
and SNP20 rs1333049 (p=0.0417).  The genotype TT for SNP10 MYH13/rs2074877, and CC for 
SNP 20 rs1333049  had the latest AAO.  The heterozygotes (CT and GC) did not seem to have 
similar ages at onset, suggesting a possible recessive pattern.   
 
Table 3.7. Analysis of variance of 22 SNPs for AAO, taking into account APOE status and gender 
 Mean age of onset according to Genotypes p-value 
SNP1 GALP   
rs3745833     
            CC(413)                 CG (444)                GG(113) p 
73.13 ± 6.34 72.62 ± 5.89 72.79 ± 5.69 0.480 
SNP2 PCK1   
rs8192708          
            AA(775)                  AG(134)                GG(62) p 
72.83 ± 6.13 72.98 ± 6.18 72.64 ± 5.01 0.961 
SNP3 TNK1 
rs1554948          
            AA(178)                 AT(491)                  TT(302) p 
72.34 ± 6.00 73.00 ± 6.16 72.91 ± 5.99 0.459 
SNP4 SERPINA13 
rs11622883          
           AA(206)                  AT(483)                  TT(280) p 
72.84 ± 6.28 72.90 ±  5.90 72.75 ± 6.24 0.948 
SNP5 PGBD1   
rs3800324          
           AA(0)                      AG(81)                    GG(890) p 
NA 73.43 ± 5.88 72.80 ± 6.09 0.366 
SNP6 LAMIN AC 
rs505058          
           CC(16)                     CT(68)                    TT(787) p 
70.45 ± 6.83 72.74 ± 6.27 72.92 ± 6.01 0.265 
SNP7 UBD  
rs444013       
           CC(245)                   CG(505)                   GG(221) p 
72.57 ± 5.95 72.75 ± 6.03 73.37 ± 6.29 0.313 
SNP8 
rs1859849  
           CC(56)                    CG(378)                   GG(537) p 
73.93 ± 5.92 73.11 ± 6.19 72.54 ± 6.00 0.147 
SNP9 BCR 
rs9608099        
            CC(92)                    CT(443)                   TT(433) p 
73.68 ± 5.80 72.76 ± 6.11 72.79 ± 6.09 0.399 
SNP10 MYH13 
rs2074877          
            CC(389)                  CT(448)                   TT(134)  
72.65 ± 6.14 72.50 ± 5.88 74.55 ± 6.27 0.00196 
SNP11 EBF3   
rs11016976          
            CC(22)                    CT(249)                   TT(700) p 
74.19 ± 7.16 73.02 ± 5.98 72.74 ± 6.07 0.4703 
SNP12 AGC1 
rs2882676              
            AA(140)                 AC(438)                   CC(391) p 
73.28 ± 5.89 72.61 ± 6.18 72.95 ± 6.03 0.4806 
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Table 3.7 continued: 
SNP13 CTSS 
 
           AA(826)                  AG(137)                   GG(8) p 
72.94 ± 6.09 72.25 ± 5.96 72.99 ± 7.01 0.468 
SNP14 FAM63A 
 
           AA(6)                       AT(113)                   TT(851) P 
75.32 ± 4.49 72.14 ± 5.79 72.92 ± 6.12 0.265 
SNP15 TRAK2  
rs13022344          
            CC(105)                  CT(439)                    TT(427) p 
73.13 ± 6.61 72.58 ± 6.02 73.05 ± 6.00 0.469 
SNP 16 
rs6907175 
            AA(255)                 AG(421)                   GG(256) p 
72.42 ± 5.81 73.19 ± 6.24 73.05 ± 6.16 0.272 
SNP17 
rs501120 
            CC(18)                    CT(249)                    TT(703) p 
72.66 ±. 6.85 73.26 ± 6.28 72.71 ± 5.98 0.466 
SNP18  
rs2943634 
           AA(124)                  CA(410)                    CC(428) p 
73.33 ± 5.98 72.66 ± 6.06 72.90 ± 6.11 0.547 
SNP19 SMAD3 
rs17228212 
           CC(73)                     TC(363)                    TT(535) p 
72.54 ± 5.91 72.94 ± 5.99 72.82 ± 6.16 0.869 
SNP20  
rs1333049 
           CC(241)                   GC(471)                  GG(259) p 
73.64 ± 6.45 72.43 ± 5.85 72.87 ± 6.05 0.0417 
SNP21 MTHRD1L 
rs6922269 
           AA(69)                    AG(381)                   GG(520) p 
71.74 ± 5.31 72.75 ± 6.08 73.07 ± 6.16 0.216 
SNP22 TCF7L2 
rs7901695 
           CC(92)                     CT(409)                    TT(470) p 
72.64 ± 6.08 72.72 ± 6.04 73.00 ± 6.11 0.751 
 
3.9 ANALYSIS OF VARIANCE OF 22 SNPS FOR BASELINE MINI MENTAL 
STATE EXAM (MMSE) SCORE 
APOE-adjusted mean value of baseline MMSE score among AD cases and controls for 
each SNP are given in Table 3.8.  Analysis of variance (ANOVA) was used in order to determine 
if the mean of a variable was significantly different between genotypes.  The ANOVA 
calculation for baseline MMSE score showed a statistically significant difference between 
genotypes for SNP20 rs133049 (p=0.025).  The genotype GG had the lowest baseline MMSE 
score, the data does not seem to support a dosage effect model. 
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Table 3.8. Analysis of variance of 22 SNPs for baseline MMSE score, taking into account disease and APOE 
status, gender and AAO 
 MMSE according to Genotypes p-value 
SNP1 GALP   
rs3745833     
          CC( 787)                    CG(878)                   GG(224) p 
23.10 ± 6.02 23.13 ± 6.16 23.60 ± 5.88 0.243 
SNP2 PCK1   
rs8192708          
          AA(1468)                    AG(293)                  GG(133) p 
23.04 ± 6.12 23.57 ± 6.11 23.91 ± 5.42 0.711 
SNP3 TNK1 
rs1554948          
          AA(387)                      AT(913)                   TT(592) p 
23.77 ± 6.13 22.93 ± 6.08 23.18 ± 5.99 0.552 
SNP4 SERPINA13 
rs11622883          
          AA(405)                     AT(939)                    TT(544) p 
22.89 ± 6.27 23.19 ± 6.09 23.36 ± 5.92 0.409 
SNP5 PGBD1   
rs3800324          
         AA(3)                        AG(152)                   GG(1734) p 
25.30 ± 1.59 22.94 ± 6.32 23.19 ± 6.06 0.999 
SNP6 LAMIN AC 
rs505058          
        CC(23)                       CT(323)                    TT(1545) p 
21.44 ± 6.24 23.44 ± 5.84 23.15 ± 6.12 0.306 
SNP7 UBD  
rs444013       
         CC(504)                     CG(954)                   GG(434) p 
23.36 ± 6.05 23.04 ± 6.04 23.19 ± 6.21 0.857 
SNP8 
rs1859849  
        CC(131)                    CG(711)                   GG(1048) p 
24.65 ± 5.28 22.94 ± 6.21 23.14 ± 6.05 0.233 
SNP9 BCR 
rs9608099        
        CC(181)                     CT(837)                   TT(861) p 
23.11 ± 6.02 23.02 ± 6.13 23.32 ± 6.05 0.817 
SNP10 MYH13 
rs2074877          
        CC(743)                    CT(890)                    TT(257) P 
22.81 ± 6.30 23.50 ± 5.91 23.09 ± 5.94 0.159 
SNP11 EBF3   
rs11016976          
        CC(45)                      CT(449)                    TT(1398) p 
23.35 ± 6.87 23.10 ± 5.80 23.20 ± 6.14 0.323 
SNP12 AGC1 
rs2882676              
        AA(263)                    AC(855)                   CC(764) p 
23.05 ± 5.72 23.22 ± 6.20 23.15 ± 6.06 0.853 
SNP13 CTSS 
 
        AA(1602)                 AG(279)                    GG(10) p 
23.16 ± 6.04 23.50 ± 603 17.24 ± 10.02 0.086 
SNP14 FAM63A 
 
         AA(7)                        AT(239)                   TT(1646) P 
18.27 ± 8.12 23.79 ± 5.87 23.12 ± 6.08 0.228 
SNP15 TRAK2  
rs13022344          
         CC(208)                    CT(844)                    TT(836) p 
23.58 ± 5.78 23.09 ± 6.25 23.15 ± 5.97 0.421 
SNP 16 
rs6907175 
         AA(206)                    AG(333)                   GG(200) p 
20.93 ± 5.36 21.41 ± 5.44 21.14 ± 5.94 0.845 
SNP17  
rs501120 
         CC(18)                       CT(187)                    TT(565) p 
21.46 ± 4.79 21.02 ± 5.35 21.13 ± 5.73 0.828 
SNP18  
rs2943634 
         AA(93)                      CA(314)                    CC(358) p 
21.16 ± 5.17 20.97 ± 5.39 21.20 ± 5.91 0.796 
SNP19 SMAD3 
rs17228212 
        CC(59)                       TC(298)                   TT(414) p 
21.83 ± 4.98 21.10 ± 5.44 21.02 ± 5.81 0.807 
SNP20  
rs1333049 
        CC(193)                      GC(386)                 GG(192) p 
22.02 ± 5.39 20.92 ± 5.64 20.58 ± 5.69 0.025 
SNP21 MTHRD1L 
rs6922269 
        AA(70)                        AG(303)                 GG(397) p 
20.59 ± 5.94 21.36 ± 5.62 21.01 ± 5.55 0.135 
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SNP22 TCF7L2 
rs7901695 
        CC(72)                       CT(307)                  TT(392) p 
21.33 ± 4.63 21.19 ± 5.76 21.01 ± 5.66 0.772 
 
3.10 ANALYSIS OF VARIANCE OF 22 SNPS FOR CHANGE IN MINI MENTAL 
STATE EXAM (MMSE) SCORE 
APOE-adjusted mean value of change in MMSE score among AD cases and controls for 
each SNP are given in Table 3.9.  Change in MMSE score was calculated as the final – initial 
MMSE score.  The length of time between the final and initial assessment varied between 
individuals, this was adjusted for in the model.  Analysis of variance (ANOVA) was used in 
order to determine if the mean of a variable was significantly different between genotypes.  The 
ANOVA calculation for change in MMSE score did not reveal any SNPs with statistically 
significant difference between genotypes. 
 
Table 3.9. Analysis of variance of 22 SNPs for MMSE score change, taking into account disease and APOE 
status, gender and AAO 
 MMMSE change according to Genotypes p-value 
SNP1 GALP   
rs3745833     
             CC(313)                           CG(338)                     GG(92) p 
-4.19 ± 5.17 -4.68 ± 5.29 -4.64 ± 4.78 0.267 
SNP2 PCK1   
rs8192708          
             AA(584)                          AG(110)                     GG(49) p 
-4.45 ± 5.15 -3.99 ± 4.94 -5.76 ± 5.89 0.122 
SNP3 TNK1 
rs1554948          
             AA(150)                           AT(372)                       TT(222) p 
-4.63 ± 5.53 -4.26 ± 5.08 -4.70 ± 5.11 0.548 
SNP4 SERPINA13 
rs11622883          
            AA(158)                            AT(367)                      TT(218) p 
-4.56 ± 4.66 -4.63 ± 5.47 -4.12 ± 5.04 0.788 
SNP5 PGBD1   
rs3800324          
            AA(1)                             AG(59)                        GG(684) p 
-0.652 ± NA -4.21 ± 5.17 -4.49 ± 5.18 0.687 
SNP6 LAMIN AC 
rs505058          
            CC(7)                                CT(142)                       TT(595) p 
-4.01 ± 3.33 -4.48 ± 4.96 -4.47 ± 5.25 0.800 
SNP7 UBD                  CC(183)                         CG(389)                     GG(169) p 
Table 3.8 continued: 
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rs444013       -4.43 ± 4.75 -4.45 ± 5.21 -4.62 ± 5.59 0.782 
SNP8 
rs1859849  
           CC(51)                               CG(277)                      GG(415) p 
-4.57 ± 6.41 -4.22 ± 4.97 -4.63 ± 5.15 0.076 
SNP9 BCR 
rs9608099        
           CC(72)                              CT(331)                       TT(337) p 
-4.35 ± 5.35 -4.45 ± 4.82 -4.51 ± 5.49 0.837 
SNP10 MYH13 
rs2074877          
           CC(294)                            CT(341)                       TT(108) P 
-4.44 ± 4.97 -4.76 ± 5.41 -3.69 ± 4.94 0.121 
SNP11 EBF3   
rs11016976          
           CC(21)                              CT(189)                       TT(534) p 
-3.31 ± 4.44 -4.47 ± 5.22 -4.51 ± 5.19 0.552 
SNP12 AGC1 
rs2882676              
           AA(105)                            AC(332)                      CC(304) p 
-5.23 ± 5.78 -4.27 ± 5.09 -4.42 ± 5.06 0.457 
SNP13 CTSS 
 
          AA(635)                             AG(106)                      GG(3) p 
-4.51 ± 5.18 -4.12 ± 5.06 -7.28 ± 8.86 0.811 
SNP14 FAM63A 
 
          AA(3)                                 AT(85)                         TT(656)  
-7.28 ± 8.86 -4.32 ± 5.30 -4.47 ± 5.15 0.748 
SNP15 TRAK2  
rs13022344          
          CC(83)                                CT(330)                       TT(331) p 
-4.04 ± 5.19 -4.49 ± 5.14 -4.55 ± 5.23 0.819 
SNP 16 
rs6907175 
          AA(203)                             AG(321)                       GG(194) p 
-4.63 ± 5.50 -3.96 ± 4.99 -5.02 ± 5.11 0.314 
SNP17  
rs501120 
          CC(17)                                CT(180)                        TT(5.17) p 
-4.11 ± 5.24 -4.51 ± 5.22 -4.43 ± 5.17 0.814 
SNP18  
rs2943634 
          AA(91)                                CA(304)                       CC(348) p 
-5.21 ± 5.03 -4.27 ± 4.92 -4.40 ± 5.41 0.264 
SNP19 SMAD3 
rs17228212 
          CC(59)                                 TC(287)                       TT(403) p 
-4.13 ± 5.19 -4.69 ± 5.37 -4.32 ± 5.04 0.442 
SNP20  
rs1333049 
          CC(188)                               GC(375)                      GG(186) p 
-3.94 ± 5.03 -4.43 ± 5.06 -5.01 ± 5.52 0.354 
SNP21 MTHRD1L 
rs6922269 
          AA(67)                                 AG(295)                      GG(386) p 
-4.43 ± 5.58 -4.07 ± 4.63 -4.73 ± 5.49 0.209 
SNP22 TCF7L2 
rs7901695 
          CC(71)                                  CT(300)                       TT(378) p 
-4.11 ± 5.89 -4.63 ± 5.29 -4.37 ± 4.94 0.615 
 
3.11 ANALYSIS OF VARIANCE OF 22 SNPS FOR DISEASE DURATION 
APOE-adjusted mean value of disease duration among AD cases for each SNP is given in 
Table 3.10.  Analysis of variance (ANOVA) was used in order to determine if the mean of a 
variable is significantly different between genotypes.  The ANOVA calculation for disease 
duration showed a statically significant difference between genotypes for SNP13 CTSS 
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(p=0.0006) and SNP14 FAM63A (p=0.0014).  In both SNPs the heterozygotes had a shorter 
duration of disease.  Both of these SNPs had no homozygotes for the minor allele, therefore we 
are not able to fully investigate a dosage or dominant model.  The number of genotypes analyzed 
is small compared to the whole population, due to the fact that we only have disease duration for 
those patients that were confirmed with autopsy and we have their date at onset and date at death. 
 
Table 3.10. Analysis of variance of 22 SNPs for disease duration (age at death - age at onset), taking into 
account APOE status, gender and AAO 
 Disease duration according to Genotypes p-value 
SNP1 GALP   
rs3745833     
           CC(41)                       CG(29)                      GG(10) p 
9.84 ± 3.46 8.88 ± 4.54 8.62 ± 3.05 0.479 
SNP2 PCK1   
rs8192708          
           AA(64)                      AG(15)                       GG(1) p 
9.71 ± 3.71 7.88 ± 4.23 7.21 ± NA 0.221 
SNP3 TNK1 
rs1554948          
           AA(15)                      AT(44)                        TT(21) p 
9.61 ± 3.13 9.19 ± 3.67 9.46 ± 4.69 0.923 
SNP4 SERPINA13 
rs11622883          
           AA(21)                      AT(29)                        TT(30) p 
10.29 ± 4.23 8.69 ± 3.11 9.29 ± 4.15 0.344 
SNP5 PGBD1   
rs3800324          
           AA(0)                        AG(7)                         GG(73) p 
NA 6.93 ± 2.50 9.57 ± 3.87 0.084 
SNP6 LAMIN AC 
rs505058          
           CC(0)                         CT(11)                        TT(69) p 
NA 8.03 ± 3.21 9.55 ± 3.90 0.234 
SNP7 UBD  
rs444013       
           CC(20)                       CG(43)                       GG(17) p 
9.46 ± 2.39 9.30 ± 4.48 9.29 ± 3.61 0.987 
SNP8  
rs1859849  
          CC(6)                          CG(27)                       GG(47) p 
7.81 ± 3.44 10.51 ± 4.18 8.86 ± 3.57 0.118 
SNP9 BCR 
rs9608099        
          CC(6)                          CT(34)                        TT(39) p 
11.30 ± 6.29 9.81 ± 3.76 8.58 ± 3.40 0.149 
SNP10 MYH13 
rs2074877          
          CC(25)                        CT(43)                        TT(12) p 
8.87 ± 4.75 9.36 ± 3.38 12.22 ± 3.35 0.604 
SNP11 EBF3   
rs11016976          
            CC(3)                        CT(21)                         TT(56) p 
10.73 ± 8.55 8.71 ± 3.01 9.50 ± 3.86 0.604 
SNP12 AGC1 
rs2882676              
           AA(8)                        AC(41)                         CC(31) p 
7.86 ± 3.85 9.47 ± 3.80 9.54 ± 3.91 0.533 
SNP13 CTSS 
 
          AA(69)                       AG(11)                        GG(0) p 
9.80 ± 3.81 6.44 ± 2.61 NA 0.006 
SNP14 FAM63A 
 
          AA(0)                         AT(8)                           TT(72)  
NA 5.37 ± 2.03 9.78 ± 3.74 0.0014 
SNP15 TRAK2  
rs13022344          
         CC(6)                           CT(40)                         TT(34) p 
11.79 ± 2.17 9.74 ± 4.20 8.42 ± 3.38 0.093 
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SNP16  
rs6907175 
          AA(15)                       AG(22)                        GG(17) p 
9.58 ± 4.21 10.00 ± 2.43 11.27 ± 4.15 0.395 
SNP17  
rs501120 
          CC(0)                          CT(19)                         TT(38) P 
NA 8.97 ± 4.17 10.96 ± 3.38 0.053 
SNP18  
rs2943634 
          AA(11)                       CA(21)                         CC(25) p 
10.74 ± 4.49 9.94 ± 3.57 10.40 ± 3.67 0.840 
SNP19 SMAD3 
rs17228212 
          CC(1)                         TC(22)                          TT(34) p 
5.27 ± NA 10.76 ± 4.16 10.14 ± 3.45 0.346 
SNP20  
rs1333049 
          CC(15)                       GC(24)                         GG(18) p 
10.39 ± 4.70 10.43 ± 3.64 10.04 ± 3.16 0.943 
SNP21 MTHRD1L  
rs6922269 
          AA(5)                         AG(18)                        GG(34) p 
9.75 ± 5.88 11.04 ± 4.21 9.98 ± 3.17 0.600 
SNP22 TCF7L2 
rs7901695 
          CC(4)                         CT(21)                         TT(32) p 
11.00 ± 5.27 11.30 ± 4.05 9.55 ± 3.28 0.227 
  
3.12 POWER CALCULATION AT α 0.05 FOR EXAMINED SNPS 
80% power at α 0.05 for 1,000 cases and 1,000 controls to detect a risk or protective allele 
reflected by odds ratios is given in Table 3.11. As indicated in the table our sample size had 
sufficient power to detect small differences.  For 12 SNPs power was sufficient to detect an OR 
of 1.2 or lower.  For the other 10 SNPs, power was sufficient to detect ORs between 1.22 and 
1.42. 
Table 3.11. 80% Power Calculation at α 0.05 for 22 SNPs 
SNP > Odds Ratio for risk 
allele 
> Odds Ratio for 
protective allele 
SNP 1 GALP   rs3745833     1.1553 0.8684 
SNP 2 PCK1   rs8192708          1.2608 0.8087 
SNP 3 TNK1  rs1554948          1.1452 0.8721 
SNP 4 SERPINA13  rs11622883          1.1452 0.8727 
SNP 5 PGBD1   rs3800324          1.4134 0.6614 
SNP 6 LAMIN AC  rs505058          1.3145 0.7325 
SNP 7 UBD  rs444013       1.1453 0.8732 
SNP 8  rs1859849  1.1729 0.8464 
SNP 9 BCR  rs9608099        1.1634 0.8547 
Table 3.10 continued:  
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SNP 10 MYH13  rs2074877          1.1544 0.8689 
SNP 11 EBF3  rs11016976          1.2178 0.8083 
SNP 12 AGC1 rs2882676              1.1517 0.8654 
SNP 13 CTSS 1.2769 0.8007 
SNP 14 FAM63A 1.2583 0.7758 
SNP 15 TRAK2  rs13022344          1.1562 0.8613 
SNP 16  rs6907175 1.1475 0.8696 
SNP 17 rs501120 1.4198 0.6680 
SNP 18 rs2943634 1.2967 0.7625 
SNP 19 SMAD3 rs17228212 1.3059 0.7541 
SNP 20 rs1333049 1.2851 0.7767 
SNP 21 MTHRD1L rs6922269 1.3235 0.7398 
SNP 22 TCF7L2 rs7901695 1.3181 0.7440 
 
We used the risk alleles identified in the paper and coded our population in order to 
determine how many risk alleles they carried total (assuming a dosage model) and how many 
loci contained a risk allele (assuming a dominant model).  We carried out a linear regression for 
each model adjusting for age, sex and APOE status.  The analysis testing a dosage model was not 
statistically significant with a p value of 0.80420.  The analysis testing a dominant model was not 
statistically significant with a p value of 0.63398.    
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4.0  DISCUSSION 
Alzheimer’s disease is the most common form of dementia in the elderly, and has a significant 
effect on public health in the United States.  Although AD has been described for more than 100 
years, no effective treatment has been described.  Late onset AD is a complex disorder in which 
gene-gene as well as gene-environment interactions are involved in the etiology of the disease.  
Although the exact etiology of AD has not been identified first-degree relatives of individuals 
with AD have been found to have an increased risk of developing the disease.  A risk of 15-19% 
was seen in first-degree relatives of probands with AD as compared to a risk of 5% in the general 
population (a 3-4 fold increase in risk) (Liddell et al., 2001).  Despite the evidence of substantial 
genetic effect on LOAD, to date the only known genetic risk factor is APOE.   
In a genome wide association study examining 17,343 putative functional SNPs located 
in 11221 unique genes, 19 SNPs were found to have a statistically significant association with 
AD (Grupe et al., 2007).  Three of these SNPs included the APOE polymorphism and two linked 
polymorphisms in the TOMM40 and APOC2 genes.  Our goal was to replicate the 16 new 
associations in a large case-control sample of white Americans.  Additionally we examined six 
positional and/or biological candidates as risk factors for AD (SNPs 17-22).  The secondary 
goals of the study were to examine the association of 22 SNPs with quantitative traits linked to 
AD, including AAO, MMSE score and disease duration.  
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We did not observe a statistically significant association between the SNPs and the risk of 
AD in our primary analysis.  Our data suggest that the association in the 16 previously identified 
SNPs, if it exists, is not statistically significant in our study population.  Furthermore, the 
additional six SNPs in positional and biological candidate regions for AD also showed no 
association.  Our sample size had sufficient power to detect relatively small effect sizes.  We 
found some significant associations when data were stratified.  Considering we performed 
multiple testing, however, these associations could be due to chance.   
Genome wide association studies allow us to detect new genes for a disease not 
previously implicated based on the known biology of the disease.  These studies may shed light 
on novel genes and SNPs that affect risk for complex diseases.  Grupe et al. (2007) examined the 
whole genome for association of putative functional variants, instead of examining variants that 
are known biological and/or positional candidates.  Many possible associations have been found 
without the immediate knowledge of their biological link to the disease.  This information may 
help us understand the disease biology in greater detail in the future (Drazen et al., 2007).   
There are many difficulties when using whole genome wide association studies to 
identify candidate genes for complex diseases (Baron, 2001).  It may be difficult to differentiate 
between genes with true association and those that are more common due to ethnic variation.  
Our study was ethnically homogenous because patients were of Caucasian decent, and from a 
single geographical location.  Similarly, the population from Grupe et al. (2007) was also of 
Caucasian descent. However, the category “Caucasian” is broad, and individuals may still vary 
widely in genetic history and therefore significant genetic variation may be present. 
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Alzheimer’s disease has several possible confounding factors, such as how the condition 
is diagnosed.  Clinical diagnoses are made based on physical exam and MMSE scores.  There are 
numerous types of dementia, and AD can only be differentiated from these other conditions with 
an autopsy and pathological examination of the brain tissue.  Although only ~4.5% of our 
patients had a diagnosis of AD confirmed by autopsy, our Alzheimer’s Disease Research Center 
has found a high correlation (>95%) between clinically diagnosed AD cases and those confirmed 
at autopsy.  
In complex diseases genes do not generally act in a simple additive manner, but through 
complex networks with gene-gene and gene-environment interactions (Colhoun et al., 2003).  
According to Calhoun et al. (2003) “if the effect of genotype on disease risk is entirely restricted 
to people exposed to the environmental factor, and prevalence of this exposure varies twofold 
between populations, a twofold variation in average effect size of genotype on disease risk would 
exist”.  Environmental factors can confound studies that are investigating genetic risk, due to the 
fact that they are numerous and hard to control for.   
It is possible that linkage disequilibrium played a large role in why no associations were 
found.  It is possible that in the original studies the SNPs found to have a significant association 
were in LD with the causal risk allele.  It is also possible that our population did not have this 
same LD, with the risk allele at the same SNP.  This LD could be with another SNP on the same 
gene or could not exist at all with our specific population (Colhoun et al., 2003).  
In 2007 it has been estimated that 5.1 million Americans have AD, 4.9 million of these 
individuals are age 65 or older (Alzheimer’s association, 2007).  Advances in medicine have lead 
to more individuals living into their 80s and 90s.  The risk of AD increases with age, therefore 
the number of persons with the disease is expected to grow as individuals continue to live longer.  
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In 2005, Medicare spent $91 billion on AD and other dementias, projected to increase to $160 
and $189 billion in 2010 and 2015 (Alzheimer’s Association, 2007).  State and federally funded 
Medicaid spent $21 billion in 2005 on Alzheimer’s and other dementias.  This is projected to 
increase to $24 and $27 billion in 2010 and 2015 respectively (Alzheimer’s Association, 2007).    
Finding genes associated with AD will help us target those at risk.  Preventative measures could 
be taken in order to delay the onset of the disease, and lessen the financial burden on the health 
care system.  Even small reduction in risks for common diseases may have major public health 
significance (Merikangas et al., 2004).   
There are different strategies used to replicate the data from a whole genome wide study.  
An exact replication strategy attempts to replicate the results from a past study exactly, looking 
specifically at the SNPs identified as possible risk alleles.  This type of strategy is balanced in 
terms of cost and the ability to replicate a maximum number of loci (Clarke et al., 2007). Our 
study design was an exact strategy.  This design is focused and may have missed any other SNPs 
in these genes with an association with the risk of AD.   
Another possible strategy includes the exact replication of risk SNPs as well as 
surrounding SNPs in the same gene, this has been called a local replication strategy.  This study 
design is more costly but may have the ability to pick up associations missed by the exact 
strategy.  This design may have the ability identify associations that may be masked under the 
exact replication strategy.  If there are other SNPs on the gene of interest in LD with a casual  
allele this study may have the ability to find them.  However, this procedure can also reveal 
different loci than those initially identified, making interpretation difficult and usually requiring 
another validation study (Clarke et al., 2007).   
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We must study these genes in much greater depth in order to examine all SNPs, with 
potential biological or positional significance.  However, even when all SNPs are studied, 
confounding factors such as the make up of the population and environment still act to affect the 
outcome of the disease. 
From a genetic counseling standpoint it is important to explore possible patient reactions 
to genetic information that may be found from similar studies.  AD has substantial physical, 
psychological and social burdens for individuals with AD and their families.  Surveys and data 
from Cupples et al. (2004) found that substantial portions of relatives of those with AD were 
interested in more fully understanding their risk.   
Current recommendations for early onset families with a clear autosomal dominant 
pattern (or a possible de novo mutation) state that individuals should have the opportunity to test 
for possible mutations in APP (research basis) PSEN1 and PSEN2 and should also be counseled 
appropriately regarding recurrence risks.  A positive PSEN1, PSEN2 or APP mutation confirms 
the etiology of an individual’s AD, but, a negative result does not rule out other genetic causes.  
Individuals may choose not to have testing due to the psychological impact it may have, 
especially because there are currently no treatments for AD (Goldman et al. 2004).  One study 
looked at the psychological effect of testing on nonsymptomatic individuals (Molinuevo et al., 
2005).  This study found that test results did lead to lifestyle changes.  One carrier decided along 
with their partner not to have any more children, while some individuals found to be negative 
sometimes decided to have more children.  One mutation carrier made some lifestyle changes 
including spending more time with his family and less time at work.  Over the two years of 
follow up neither carriers nor noncarriers made any employment, marital status or financial 
changes.  All but one positive individual’s anxiety levels returned to normal within the two year 
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follow up period.  This one individual was showing symptoms of disease and, in addition, had a 
general anxiety disorder.  Overall it was found that when testing is made available and optional it 
has the ability to benefit nonsymptomatic at risk individuals.           
Recommendations for late onset AD are not as clear.  Various groups have agreed that 
there is no role for APOE genotyping in prediction or risk assessment in relatives of those with 
LOAD (Liddell et al., 2001).  This is due to the fact that the APOE*4 allele is a risk factor and 
not a predictor of disease, it is questionable whether this information would be beneficial to 
patients.  If an individual is found to carry the risk allele there is greater than a 50% chance that 
they will not develop the disease (Liddell et al., 2001).  Individuals have the ability to modify 
possible environmental risk factors of the disease such as head trauma, tobacco and alcohol 
usage, vascular disease and cholesterol levels, however, the only known risk factor to AD is age.  
There is also no current treatment for AD, therefore it could be argued that genetic testing could 
do more harm than good.   
A test for APOE will be offered in the near future by Smart Genetics in Philadelphia 
(Couzin, 2008).  Previously, APOE testing has only been clinically available to those with 
dementia.  The REVEAL study evaluated behavioral and psychological impact of APOE 
disclosure to first degree relatives of those with AD.  The study split participants into two 
groups; one group received risk analysis based solely on their family history, the other group 
received risk analysis based on their family history and APOE status (Cupples et al., 2004).  
Researchers hypothesized that individuals who receive a positive APOE*4 test will make health 
behavior changes while those that receive a negative test or no APOE testing will not (Chao et 
al., 2008).  The study confirmed the hypothesis, showing that individuals who received a positive 
APOE*4 genotype result were more likely to make health behavior changes even after they were 
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explicitly informed that they are not proven to prevent AD.  Fewer individuals who received risk 
information solely based on family history and those that received a negative APOE*4 genotype 
result participated in these changes.  These results suggest that individuals may be more 
motivated to make health behavior changes based on genetic testing and family history, as 
opposed to family history alone, even in the absence of proven risk-reduction strategies.  Further 
research on the genetics of LOAD will allow us to counsel patients of late onset families more 
accurately about their risk. 
Future research may elucidate risk alleles for late onset AD.  Even if the risk to an 
individual is slight these findings may help us more fully understand the biology behind AD, and 
may lead to more effective treatments in the future.   
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